CA2610920A1 - Spiro-imidaznaphthyridine derivatives as gastric acid secretion inhibitors - Google Patents
Spiro-imidaznaphthyridine derivatives as gastric acid secretion inhibitors Download PDFInfo
- Publication number
- CA2610920A1 CA2610920A1 CA002610920A CA2610920A CA2610920A1 CA 2610920 A1 CA2610920 A1 CA 2610920A1 CA 002610920 A CA002610920 A CA 002610920A CA 2610920 A CA2610920 A CA 2610920A CA 2610920 A1 CA2610920 A1 CA 2610920A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- hydroxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000027119 gastric acid secretion Effects 0.000 title description 5
- 239000003112 inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- -1 cyanomethyl Chemical group 0.000 claims description 97
- 229910052739 hydrogen Inorganic materials 0.000 claims description 77
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 77
- 239000001257 hydrogen Substances 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000006329 ethyl amino carbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 4
- 210000004211 gastric acid Anatomy 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 235000013350 formula milk Nutrition 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 229940093499 ethyl acetate Drugs 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000009858 acid secretion Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229960002626 clarithromycin Drugs 0.000 description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108010079943 Pentagastrin Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000006434 Ritter amidation reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229960001040 ammonium chloride Drugs 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- VHWRFNWGYKZUKZ-UHFFFAOYSA-N ethyl 2-(2-amino-1,3-dihydroinden-2-yl)acetate;hydrochloride Chemical compound Cl.C1=CC=C2CC(CC(=O)OCC)(N)CC2=C1 VHWRFNWGYKZUKZ-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 3
- 229960000444 pentagastrin Drugs 0.000 description 3
- 229940126535 potassium competitive acid blocker Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 2
- ZWQYGVYTQQMUMT-UHFFFAOYSA-N 2,3-dimethyl-8-phenylmethoxyimidazo[1,2-a]pyridine-6-carboxylic acid Chemical compound C=1C(C(O)=O)=CN2C(C)=C(C)N=C2C=1OCC1=CC=CC=C1 ZWQYGVYTQQMUMT-UHFFFAOYSA-N 0.000 description 2
- UJNUQBFLQASHJS-UHFFFAOYSA-N 2-(2-amino-1,3-dihydroinden-2-yl)acetic acid;hydrochloride Chemical compound Cl.C1=CC=C2CC(N)(CC(O)=O)CC2=C1 UJNUQBFLQASHJS-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HWPSRHFTTNMVSS-UHFFFAOYSA-N CC=1N=C2N(C=C(C=3CCC4(NC23)CC2=CC=CC=C2C4)C(=O)OC)C1C Chemical compound CC=1N=C2N(C=C(C=3CCC4(NC23)CC2=CC=CC=C2C4)C(=O)OC)C1C HWPSRHFTTNMVSS-UHFFFAOYSA-N 0.000 description 2
- WYVJMCANKZOALY-UHFFFAOYSA-N CC=1N=C2N(CC(C=3C(CC4(NC23)CC2=CC=CC=C2C4)=O)C(=O)OC)C1C Chemical compound CC=1N=C2N(CC(C=3C(CC4(NC23)CC2=CC=CC=C2C4)=O)C(=O)OC)C1C WYVJMCANKZOALY-UHFFFAOYSA-N 0.000 description 2
- 101100178983 Caenorhabditis elegans hyl-1 gene Proteins 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- NKFUCLPIKTWBGZ-UHFFFAOYSA-N ethyl 2-(2-acetamido-1,3-dihydroinden-2-yl)acetate Chemical compound C1=CC=C2CC(CC(=O)OCC)(NC(C)=O)CC2=C1 NKFUCLPIKTWBGZ-UHFFFAOYSA-N 0.000 description 2
- YGCOFXRMEAUBGS-UHFFFAOYSA-N ethyl 2-(2-amino-1,3-dihydroinden-2-yl)acetate Chemical compound C1=CC=C2CC(CC(=O)OCC)(N)CC2=C1 YGCOFXRMEAUBGS-UHFFFAOYSA-N 0.000 description 2
- WRTWQOZLEIKMES-UHFFFAOYSA-N ethyl 2-(2-hydroxy-1,3-dihydroinden-2-yl)acetate Chemical compound C1=CC=C2CC(CC(=O)OCC)(O)CC2=C1 WRTWQOZLEIKMES-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- QXMBIMVGEAUHDM-UHFFFAOYSA-N methyl 2,3-dimethyl-8-oxo-6,7-dihydro-5h-imidazo[1,2-a]pyridine-6-carboxylate Chemical compound C1C(C(=O)OC)CC(=O)C2=NC(C)=C(C)N21 QXMBIMVGEAUHDM-UHFFFAOYSA-N 0.000 description 2
- CKRGHSNTQLWHER-UHFFFAOYSA-N methyl 8-hydroxy-2,3-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate Chemical compound C1C(C(=O)OC)CC(O)C2=NC(C)=C(C)N21 CKRGHSNTQLWHER-UHFFFAOYSA-N 0.000 description 2
- 229960004085 mosapride Drugs 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 2
- 229960004633 pirenzepine Drugs 0.000 description 2
- 150000007519 polyprotic acids Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 229960004157 rabeprazole Drugs 0.000 description 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 2
- 229960002876 tegaserod Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NYVVVBWEVRSKIU-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 NYVVVBWEVRSKIU-LREBCSMRSA-N 0.000 description 1
- ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 description 1
- NPSVXOVMLVOMDD-SXRVEDALSA-N (2s)-2-[[(3s,6s,9s,12s)-12-[[(2s)-4-[[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1h-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methyl Chemical compound C([C@H](N)C(=O)N[C@H]1CC(=O)NC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC1=O)C(=O)N[C@@H](CC(C)C)C(O)=O)C(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O NPSVXOVMLVOMDD-SXRVEDALSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- PWILYDZRJORZDR-MISYRCLQSA-N (7r,8r,9r)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(C4=NC(C)=C(C)N4C=C3)N2)OCCOC)=CC=CC=C1 PWILYDZRJORZDR-MISYRCLQSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- BAEKCMOOBVBURZ-UHFFFAOYSA-N 2',3'-dimethylspiro[1,3-dihydroindene-2,9'-8,10-dihydro-7h-imidazo[1,2-h][1,7]naphthyridine]-6'-carboxylic acid Chemical compound C1C2=CC=CC=C2CC21NC(C1=NC(=C(N1C=C1C(O)=O)C)C)=C1CC2 BAEKCMOOBVBURZ-UHFFFAOYSA-N 0.000 description 1
- 125000004797 2,2,2-trichloroethoxy group Chemical group ClC(CO*)(Cl)Cl 0.000 description 1
- 125000006345 2,2,2-trifluoroethoxymethyl group Chemical group [H]C([H])(*)OC([H])([H])C(F)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- DMTADULPJIAIEO-UHFFFAOYSA-N 2,3-dimethyl-6,7-dihydro-5h-imidazo[1,2-a]pyridin-8-one Chemical compound O=C1CCCN2C(C)=C(C)N=C21 DMTADULPJIAIEO-UHFFFAOYSA-N 0.000 description 1
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- PKDHDJBNEKXCBI-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine hydrochloride Chemical compound Cl.CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 PKDHDJBNEKXCBI-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- XPYQFIISZQCINN-QVXDJYSKSA-N 4-amino-1-[(2r,3e,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrate Chemical compound O.O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 XPYQFIISZQCINN-QVXDJYSKSA-N 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- GHVIMBCFLRTFHI-UHFFFAOYSA-N 8-[(2,6-dimethylphenyl)methylamino]-n-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound C=1C(C(=O)NCCO)=CN2C(C)=C(C)N=C2C=1NCC1=C(C)C=CC=C1C GHVIMBCFLRTFHI-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- HMNVEJNKSLFGFK-UHFFFAOYSA-N CC=1N=C2N(C=C(C=3C(CC4(NC23)CC2=CC=CC=C2C4)=O)C(=O)OC)C1C Chemical compound CC=1N=C2N(C=C(C=3C(CC4(NC23)CC2=CC=CC=C2C4)=O)C(=O)OC)C1C HMNVEJNKSLFGFK-UHFFFAOYSA-N 0.000 description 1
- 108091005932 CCKBR Proteins 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108010092101 MEN 11420 Proteins 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- WVTGPBOMAQLPCP-GSVOUGTGSA-O [(2r)-3-amino-2-fluoropropyl]-hydroxy-oxophosphanium Chemical compound NC[C@@H](F)C[P+](O)=O WVTGPBOMAQLPCP-GSVOUGTGSA-O 0.000 description 1
- BMDFKRNKFIWLGH-UHFFFAOYSA-N [N]N1CCNCC1 Chemical group [N]N1CCNCC1 BMDFKRNKFIWLGH-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229940088506 buscopan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000006226 butoxyethyl group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004789 chlorodifluoromethoxy group Chemical group ClC(O*)(F)F 0.000 description 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 1
- 229960002099 cilansetron Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SGDINNZGYDHHKM-UHFFFAOYSA-N dilithium;trimethylsilylazanide Chemical compound [Li+].[Li+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] SGDINNZGYDHHKM-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- XFZLCTUONFKKGV-UHFFFAOYSA-N ethyl 2,3-dimethyl-8-phenylmethoxyimidazo[1,2-a]pyridine-6-carboxylate Chemical compound C12=NC(C)=C(C)N2C=C(C(=O)OCC)C=C1OCC1=CC=CC=C1 XFZLCTUONFKKGV-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- MVKIWCDXKCUDEH-QFIPXVFZSA-N fedotozine Chemical compound C([C@](CC)(N(C)C)C=1C=CC=CC=1)OCC1=CC(OC)=C(OC)C(OC)=C1 MVKIWCDXKCUDEH-QFIPXVFZSA-N 0.000 description 1
- 229950008449 fedotozine Drugs 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001330 gastroprokinetic effect Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 description 1
- 229950008491 ilaprazole Drugs 0.000 description 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005302 itopride Drugs 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229950010119 linaprazan Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- DVOUJRUFCBNRQW-UHFFFAOYSA-N mucoxin Chemical compound O1C(C(O)CCCCCCCCCCCCCCCCC)CC(O)C1C1OC(C(O)CCCCCC=2C(OC(C)C=2)=O)CC1 DVOUJRUFCBNRQW-UHFFFAOYSA-N 0.000 description 1
- YFSUMMMODRDMCQ-UHFFFAOYSA-N n,2',3'-trimethylspiro[1,3-dihydroindene-2,9'-8,10-dihydro-7h-imidazo[1,2-h][1,7]naphthyridine]-6'-carboxamide Chemical compound C1C2=CC=CC=C2CC21NC(C1=NC(C)=C(C)N1C=C1C(=O)NC)=C1CC2 YFSUMMMODRDMCQ-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229950000640 nepadutant Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- LECZXZOBEZITCL-UHFFFAOYSA-N revaprazan Chemical compound C1CC2=CC=CC=C2C(C)N1C(C(=C(C)N=1)C)=NC=1NC1=CC=C(F)C=C1 LECZXZOBEZITCL-UHFFFAOYSA-N 0.000 description 1
- 229950000859 revaprazan Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 description 1
- 229950004387 saredutant Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229950004825 soraprazan Drugs 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229950008375 tenatoprazole Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention provides compounds of the formula (I), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.
Description
Description Title SPIRO-IMIDAZONAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS
Technical field The invention relates to novel compounds which are used in the pharmaceutical industry as active compounds for the production of medicaments.
Background Art U.S. Patent 4,468,400 describes tricyclic imidazo[1,2-a]pyridines having different ring systems fused to the imidazopyridine skeleton, which compounds are said to be suitable for treating peptide ulcer disorders. The International Patent Applications W098/42707 (which corresponds to US pat-ent 6,197,783), W098/54188 (which corresponds to US patent 6,160,119), WO00/17200 (which corresponds to US patent 6,436,953 and 6,696,460), WO00/26217 (which corresponds to US pat-ent 6,384,048), WO 00/63211 (which corresponds to US patent 6,503,923), WO 01 /72756, WO 01 /72754 (which corresponds to US patent 6,916,825), WO 01/72755 (which corresponds to US patent 6,936,623), WO 01/72757 (which corresponds to US patent 6,696,461), (which corresponds to US patent 6,869,949), WO 03/014120, WO 03/016310, WO
03/014123, WO 03/068774, WO 03/091253, WO 05/058325, WO 05/090358 and WO 05/077949 disclose tri-cyclic imidazopyridine derivatives having a very specific substitution pattern, which compounds are likewise said to be suitable for treating gastrointestinal disorders.
Disclosure of Invention Technical problem A whole series of compounds are known from the prior art which inhibit gastric acid secretion by blockade of the H+/K+-ATPase. The compounds designated as proton pump inhibitors (PPI"s), for example omeprazole, esomeprazole, lansoprazole, pantoprazole or rabeprazole, bind irreversibly to the H+/K+-ATPase. PPI's are available as therapeutics for a long time al-ready. A new class of compounds designated as reversible proton pump inhibitors (rPPI's), as acid pump antagonists (APA's) or as potassium competitive acid blockers (P-CAB's) bind re-versibly to the H+/K+-ATPase. Although rPPI's, APA's and P-CAB's are known for more than 20 years and many companies are engaged in their development, no rPPI, APA or P-CAB is at present available for therapy. The technical problem underlying the present invention is there-fore to provide acid pump antagonists which can be used in therapy.
Technical solution The invention relates to compounds of the formula 1 N
N
NH
in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy- 1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hydroxy-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy-carbonyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, alkynyl, fluoro-1 -4C-alkyl, mono- or di-1 -4C-alkylamino-1 -4C-alkyl or cyanomethyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-alkoxy-1-4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluorazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, hydroxy-1-4C-alkoxy, 1-4C-alkoxy-1 -4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxyl, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1 -4C-alkyl, halogen, hydroxyl, trifluoromethyl, halo-1 -4C-alkoxy, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alk-ylcarbonylamino, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or sulfonyl, and their salts.
1-4C-Alkyl represents straight-chain or branched alkyl groups having 1 to 4 carbon atoms. Ex-amples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and the methyl group.
3-7C-Cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl, cyclobutyl and cyclopentyl are preferred.
3-7C-Cycloalkyl-1 -4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one of the aforementioned 3-7C-cycloalkyl groups.
Examples which may be mentioned are the cyclopropylmethyl, the cyclohexylmethyl and the cyclo-hexylethyl group.
1-4C-Alkoxy represents groups, which in addition to the oxygen atom contain a straight-chain or branched alkyl group having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy group.
1-4C-Alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is sub-stituted by one of the aforementioned 1-4C-alkoxy groups. Examples which may be mentioned are the methoxymethyl group, the methoxyethyl group, in particular the 2-methoxyethyl group, the ethoxyethyl group, in particular the 2-ethoxyethyl group, and the butoxyethyl group, in par-ticular the 2-butoxyethyl group.
1-4C-Alkoxycarbonyl (-CO-1-4C-alkoxy) represents a carbonyl group, to which one of the aforementioned 1-4C-alkoxy groups is bonded. Examples which may be mentioned are the methoxycarbonyl (CH3O-C(O)-) and the ethoxycarbonyl group (CH3CHZO-C(O)-) .
2-4C-Alkenyl represents straight-chain or branched alkenyl groups having 2 to 4 carbon atoms.
Examples which may be mentioned are the 2-butenyl, 3-butenyl, 1 -propenyl and the 2-propenyl group (allyl group).
2-4C-Alkynyl represents straight-chain or branched alkynyl groups having 2 to 4 carbon atoms.
Examples which may be mentioned are the 2-butynyl, 3-butynyl, and preferably the 2-propynyl, group (propargyl group).
Fluoro-1 -4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one or more fluorine atoms. Examples which may be mentioned are the trifluoromethyl group, the difluoromethyl, the 2-fluoroethyl, the 2,2-difluoroethyl or the 2,2,2-trifluoroethyl group.
Hydroxy-1 -4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substi-tuted by a hydroxy group. Examples which may be mentioned are the hydroxymethyl, the 2-hy-droxyethyl, the 3-hydroxypropyl, the (2S)-2-hydroxypropyl and the (2R)-2-hydroxypropyl group.
Hydroxy-1 -4C-alkyl within the scope of the invention is understood to include 1-4C-alkyl groups substituted by two or more hydroxy groups. Examples which may be mentioned are the 3,4-di-hydroxybutyl and in particular the 2,3-dihydroxypropyl groups.
Halogen within the meaning of the invention is bromo, chloro and fluoro.
Mono- or di-1 -4C-alkylamino radicals contain, in addition to the nitrogen atom, one or two of the abovementioned 1-4C-alkyl radicals. Preference is given to di-1 -4C-alkylamino and in par-ticular to dimethyl-, diethyl- or diisopropylamino.
Mono- or di-1 -4C-alkylamino-1 -4C-alkyl denotes one of the abovementioned 1-4C-alkyl radi-cals which is substituted by one of the abovementioned mono- or di-1 -4C-alkylamino radicals.
Preferred mono- or di-1 -4C-alkylamino-1 -4C-alkyl radicals are the mono- or di-1 -4C-alkylaminomethyl radicals. An Example which may be mentioned is the dimethylaminomethyl (CH3)2N-CH2 radical.
1-4C-Alkoxy-1-4C-alkoxy represents one of the aforementioned 1-4C-alkoxy groups, which is substituted by a further 1-4C-alkoxy group. Examples which may be mentioned are the groups 2-(methoxy)ethoxy (CH3-O-CHZ-CHZ-O-) and 2-(ethoxy)ethoxy (CH3-CHZ-O-CHZ-CHZ -O-).
1-4C-Alkoxy-1-4C-alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkoxyl-4C-alkyl groups, which is substituted by one of the aforementioned 1-4C-alkoxy groups. An exam-ple which may be mentioned is the group 2-(methoxy)ethoxymethyl (CH3-O-CH2-CH2-O-CH2-).
Fluoro-1-4C-alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by a fluoro-1 -4C-alkoxy group. Fluoro-1 -4C-alkoxy in this case represents one of the aforementioned 1-4C-alkoxy groups, which substituted by one or more fluorine atoms. Ex-amples of fluoro-substituted 1-4C-alkoxy groups which may be mentioned are the 2-fluoro-ethoxy, 1,1,1,3,3,3-hexafluoro-2-propoxy, the 2-trifluoromethyl-2-propoxy, the 1,1,1-trifluoro-2-propoxy, the perfluoro-tert-butoxy, the 2,2,3,3,4,4,4-heptafluoro-1 -butoxy, the 4,4,4-trifluoro-1 -butoxy, the 2,2,3,3,3-pentafluoropropoxy, the perfluoroethoxy, the 1,2,2-trifluoroethoxy, in par-ticular the 1,1,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and prefera-bly the difluoromethoxy group. Examples of fluoro-1 -4C-alkoxy-1 -4C-alkyl radicals which may be mentioned are, 1,1,2,2-tetrafluoroethoxymethyl, the 2,2,2-trifluoroethoxymethyl, the trifluo-romethoxymethyl, 2-fluoroethoxyethyl, the 1,1,2,2-tetrafluoroethoxyethyl, the 2,2,2-trifluoroeth-oxyethyl, the trifluoromethoxyethyl and preferably the difluoromethoxymethyl and the difluoro-methoxyethyl radicals.
1-4C-Alkylcarbonyl represents a group, which in addition to the carbonyl group contains one of the aforementioned 1-4C-alkyl groups. An example which may be mentioned is the acetyl group.
1-4C-Alkylcarbonyl-1-4C-alkyl represents aforementioned 1-4C-alkyl groups which are substi-tuted by 1-4C-alkylcarbonyl group. Examples which may be mentioned are the 2-oxo-propyl, the 2-oxo-butyl, the 2-oxo-pentyl, the 3-oxo-butyl or the 3-oxo-pentyl radicals.
Hydroxy-1 -4C-alkoxy represents aforementioned 1-4C-alkoxy groups, which are substituted by a hydroxy group. A preferred example which may be mentioned is the 2-hydroxyethoxy group.
2-4C-Alkenyloxy represents groups, which in addition to the oxygen atom contain one of the abovementioned 2-4C-alkenyl groups. Examples, which may be mentioned, are the 2-butenyl-oxy, 3-butenyloxy, 1 -propenyloxy and the 2-propenyloxy group (allyloxy group).
Carboxy-1 -4C-alkyl represents 1-4C-alkyl groups which are substituted by a carboxyl group.
Examples, which may be mentioned, are the carboxymethyl and the 2-carboxyethyl group.
1-4C-Alkoxycarbonyl-1-4C-alkyl represents 1-4C-alkyl groups, which are substituted by one of the abovementioned 1-4C-alkoxycarbonyl groups. Examples, which may be mentioned, are the Methoxycarbonylmethyl and the ethoxycarbonylmethyl group.
Halo-1-4C-alkoxy represents 1-4C-alkoxy groups which are completely or mainly substituted by halogen. "Mainly" in this connection means that more than half of the hydrogen atoms in the 1-4C-alkoxy groups are replaced by halogen atoms. Halo-1-4C-alkoxy groups are primarily chloro- and/or in particular fluoro-substituted 1-4C-alkoxy groups. Examples of halogen-sub-stituted 1-4C-alkoxy groups which may be mentioned are the 2,2,2-trichloroethoxy, the hexa-chloroisopropoxy, the pentachloroisopropoxy, the 1,1,1-trichloro-3,3,3-trifluoro-2-propoxy, the 1,1,1-trichloro-2-methyl-2-propoxy, the 1,1,1-trichloro-2-propoxy, the 3-bromo-1,1,1-trifluoro-2-propoxy, the 3-bromo-1,1,1-trifluoro-2-butoxy, the 4-bromo-3,3,4,4-tetrafluoro-1 -butoxy, the chlorodifluoromethoxy, the 1,1,1,3,3,3-hexafluoro-2-propoxy, the 2-trifluoromethyl-2-propoxy, the 1,1,1-trifluoro-2-propoxy, the perfluoro-tert-butoxy, the 2,2,3,3,4,4,4-heptafluoro-1 -butoxy, the 4,4,4-trifluoro-1 -butoxy, the 2,2,3,3,3-pentafluoropropoxy, the perfluoroethoxy, the 1,2,2-tri-fluoroethoxy, in particular the 1,1,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoro-methoxy and preferably the difluoromethoxy group.
Mono- or di-1 -4C-alkylamino represents an amino group, which is substituted by one or by two - identical or different - groups from the aforementioned 1-4C-alkyl groups.
Examples which may be mentioned are the dimethylamino, the diethylamino and the diisopropylamino group.
1-4C-Alkylcarbonyl represents a group, which in addition to the carbonyl group contains one of the aforementioned 1-4C-alkyl groups. An example which may be mentioned is the acetyl group.
1-4C-Alkylcarbonylamino represents an amino group to which a 1-4C-alkylcarbonyl group is bonded. Examples which may be mentioned are the propionylamino (C3H7C(O)NH-) and the acetylamino group (acetamido group) (CH3C(O)NH-) .
1-4C-Alkoxycarbonylamino represents an amino group, which is substituted by one of the aforementioned 1-4C-alkoxycarbonyl groups. Examples, which may be mentioned, are the eth-oxycarbonylamino and the methoxycarbonylamino group.
1-4C-Alkoxy-1-4C-alkoxycarbonyl represents a carbonyl group, to which one of the afore-mentioned 1-4C-alkoxy-1-4C-alkoxy groups is bonded. Examples which may be mentioned are the 2-(methoxy)ethoxycarbonyl (CH3-O-CHZCHZ-O-CO-) and the 2-(ethoxy)ethoxycarbonyl group (CH3CH2-O-CH2CH2-O-CO-).
1-4C-Alkoxy-1-4C-alkoxycarbonylamino represents an amino group, which is substituted by one of the aforementioned 1-4C-alkoxy-1-4C-alkoxycarbonyl groups. Examples which may be mentioned are the 2-(methoxy)ethoxycarbonylamino and the 2-(ethoxy)ethoxycarbonylamino group.
Hydroxypyrrolidino represents a pyrrolidino group, which is substituted by a hydroxy group.
Examples which may be mentioned are the 2-hydroxypyrrolidino and the 3-hydroxypyrrolidino groups.
Hydroxyazetidino represents an azetidino group, which is substituted by a hydroxy group. An which may be mentioned is the 3-hydroxyazetidino group.
Technical field The invention relates to novel compounds which are used in the pharmaceutical industry as active compounds for the production of medicaments.
Background Art U.S. Patent 4,468,400 describes tricyclic imidazo[1,2-a]pyridines having different ring systems fused to the imidazopyridine skeleton, which compounds are said to be suitable for treating peptide ulcer disorders. The International Patent Applications W098/42707 (which corresponds to US pat-ent 6,197,783), W098/54188 (which corresponds to US patent 6,160,119), WO00/17200 (which corresponds to US patent 6,436,953 and 6,696,460), WO00/26217 (which corresponds to US pat-ent 6,384,048), WO 00/63211 (which corresponds to US patent 6,503,923), WO 01 /72756, WO 01 /72754 (which corresponds to US patent 6,916,825), WO 01/72755 (which corresponds to US patent 6,936,623), WO 01/72757 (which corresponds to US patent 6,696,461), (which corresponds to US patent 6,869,949), WO 03/014120, WO 03/016310, WO
03/014123, WO 03/068774, WO 03/091253, WO 05/058325, WO 05/090358 and WO 05/077949 disclose tri-cyclic imidazopyridine derivatives having a very specific substitution pattern, which compounds are likewise said to be suitable for treating gastrointestinal disorders.
Disclosure of Invention Technical problem A whole series of compounds are known from the prior art which inhibit gastric acid secretion by blockade of the H+/K+-ATPase. The compounds designated as proton pump inhibitors (PPI"s), for example omeprazole, esomeprazole, lansoprazole, pantoprazole or rabeprazole, bind irreversibly to the H+/K+-ATPase. PPI's are available as therapeutics for a long time al-ready. A new class of compounds designated as reversible proton pump inhibitors (rPPI's), as acid pump antagonists (APA's) or as potassium competitive acid blockers (P-CAB's) bind re-versibly to the H+/K+-ATPase. Although rPPI's, APA's and P-CAB's are known for more than 20 years and many companies are engaged in their development, no rPPI, APA or P-CAB is at present available for therapy. The technical problem underlying the present invention is there-fore to provide acid pump antagonists which can be used in therapy.
Technical solution The invention relates to compounds of the formula 1 N
N
NH
in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy- 1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hydroxy-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy-carbonyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, alkynyl, fluoro-1 -4C-alkyl, mono- or di-1 -4C-alkylamino-1 -4C-alkyl or cyanomethyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-alkoxy-1-4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluorazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, hydroxy-1-4C-alkoxy, 1-4C-alkoxy-1 -4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxyl, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1 -4C-alkyl, halogen, hydroxyl, trifluoromethyl, halo-1 -4C-alkoxy, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alk-ylcarbonylamino, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or sulfonyl, and their salts.
1-4C-Alkyl represents straight-chain or branched alkyl groups having 1 to 4 carbon atoms. Ex-amples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and the methyl group.
3-7C-Cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl, cyclobutyl and cyclopentyl are preferred.
3-7C-Cycloalkyl-1 -4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one of the aforementioned 3-7C-cycloalkyl groups.
Examples which may be mentioned are the cyclopropylmethyl, the cyclohexylmethyl and the cyclo-hexylethyl group.
1-4C-Alkoxy represents groups, which in addition to the oxygen atom contain a straight-chain or branched alkyl group having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy group.
1-4C-Alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is sub-stituted by one of the aforementioned 1-4C-alkoxy groups. Examples which may be mentioned are the methoxymethyl group, the methoxyethyl group, in particular the 2-methoxyethyl group, the ethoxyethyl group, in particular the 2-ethoxyethyl group, and the butoxyethyl group, in par-ticular the 2-butoxyethyl group.
1-4C-Alkoxycarbonyl (-CO-1-4C-alkoxy) represents a carbonyl group, to which one of the aforementioned 1-4C-alkoxy groups is bonded. Examples which may be mentioned are the methoxycarbonyl (CH3O-C(O)-) and the ethoxycarbonyl group (CH3CHZO-C(O)-) .
2-4C-Alkenyl represents straight-chain or branched alkenyl groups having 2 to 4 carbon atoms.
Examples which may be mentioned are the 2-butenyl, 3-butenyl, 1 -propenyl and the 2-propenyl group (allyl group).
2-4C-Alkynyl represents straight-chain or branched alkynyl groups having 2 to 4 carbon atoms.
Examples which may be mentioned are the 2-butynyl, 3-butynyl, and preferably the 2-propynyl, group (propargyl group).
Fluoro-1 -4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one or more fluorine atoms. Examples which may be mentioned are the trifluoromethyl group, the difluoromethyl, the 2-fluoroethyl, the 2,2-difluoroethyl or the 2,2,2-trifluoroethyl group.
Hydroxy-1 -4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substi-tuted by a hydroxy group. Examples which may be mentioned are the hydroxymethyl, the 2-hy-droxyethyl, the 3-hydroxypropyl, the (2S)-2-hydroxypropyl and the (2R)-2-hydroxypropyl group.
Hydroxy-1 -4C-alkyl within the scope of the invention is understood to include 1-4C-alkyl groups substituted by two or more hydroxy groups. Examples which may be mentioned are the 3,4-di-hydroxybutyl and in particular the 2,3-dihydroxypropyl groups.
Halogen within the meaning of the invention is bromo, chloro and fluoro.
Mono- or di-1 -4C-alkylamino radicals contain, in addition to the nitrogen atom, one or two of the abovementioned 1-4C-alkyl radicals. Preference is given to di-1 -4C-alkylamino and in par-ticular to dimethyl-, diethyl- or diisopropylamino.
Mono- or di-1 -4C-alkylamino-1 -4C-alkyl denotes one of the abovementioned 1-4C-alkyl radi-cals which is substituted by one of the abovementioned mono- or di-1 -4C-alkylamino radicals.
Preferred mono- or di-1 -4C-alkylamino-1 -4C-alkyl radicals are the mono- or di-1 -4C-alkylaminomethyl radicals. An Example which may be mentioned is the dimethylaminomethyl (CH3)2N-CH2 radical.
1-4C-Alkoxy-1-4C-alkoxy represents one of the aforementioned 1-4C-alkoxy groups, which is substituted by a further 1-4C-alkoxy group. Examples which may be mentioned are the groups 2-(methoxy)ethoxy (CH3-O-CHZ-CHZ-O-) and 2-(ethoxy)ethoxy (CH3-CHZ-O-CHZ-CHZ -O-).
1-4C-Alkoxy-1-4C-alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkoxyl-4C-alkyl groups, which is substituted by one of the aforementioned 1-4C-alkoxy groups. An exam-ple which may be mentioned is the group 2-(methoxy)ethoxymethyl (CH3-O-CH2-CH2-O-CH2-).
Fluoro-1-4C-alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by a fluoro-1 -4C-alkoxy group. Fluoro-1 -4C-alkoxy in this case represents one of the aforementioned 1-4C-alkoxy groups, which substituted by one or more fluorine atoms. Ex-amples of fluoro-substituted 1-4C-alkoxy groups which may be mentioned are the 2-fluoro-ethoxy, 1,1,1,3,3,3-hexafluoro-2-propoxy, the 2-trifluoromethyl-2-propoxy, the 1,1,1-trifluoro-2-propoxy, the perfluoro-tert-butoxy, the 2,2,3,3,4,4,4-heptafluoro-1 -butoxy, the 4,4,4-trifluoro-1 -butoxy, the 2,2,3,3,3-pentafluoropropoxy, the perfluoroethoxy, the 1,2,2-trifluoroethoxy, in par-ticular the 1,1,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and prefera-bly the difluoromethoxy group. Examples of fluoro-1 -4C-alkoxy-1 -4C-alkyl radicals which may be mentioned are, 1,1,2,2-tetrafluoroethoxymethyl, the 2,2,2-trifluoroethoxymethyl, the trifluo-romethoxymethyl, 2-fluoroethoxyethyl, the 1,1,2,2-tetrafluoroethoxyethyl, the 2,2,2-trifluoroeth-oxyethyl, the trifluoromethoxyethyl and preferably the difluoromethoxymethyl and the difluoro-methoxyethyl radicals.
1-4C-Alkylcarbonyl represents a group, which in addition to the carbonyl group contains one of the aforementioned 1-4C-alkyl groups. An example which may be mentioned is the acetyl group.
1-4C-Alkylcarbonyl-1-4C-alkyl represents aforementioned 1-4C-alkyl groups which are substi-tuted by 1-4C-alkylcarbonyl group. Examples which may be mentioned are the 2-oxo-propyl, the 2-oxo-butyl, the 2-oxo-pentyl, the 3-oxo-butyl or the 3-oxo-pentyl radicals.
Hydroxy-1 -4C-alkoxy represents aforementioned 1-4C-alkoxy groups, which are substituted by a hydroxy group. A preferred example which may be mentioned is the 2-hydroxyethoxy group.
2-4C-Alkenyloxy represents groups, which in addition to the oxygen atom contain one of the abovementioned 2-4C-alkenyl groups. Examples, which may be mentioned, are the 2-butenyl-oxy, 3-butenyloxy, 1 -propenyloxy and the 2-propenyloxy group (allyloxy group).
Carboxy-1 -4C-alkyl represents 1-4C-alkyl groups which are substituted by a carboxyl group.
Examples, which may be mentioned, are the carboxymethyl and the 2-carboxyethyl group.
1-4C-Alkoxycarbonyl-1-4C-alkyl represents 1-4C-alkyl groups, which are substituted by one of the abovementioned 1-4C-alkoxycarbonyl groups. Examples, which may be mentioned, are the Methoxycarbonylmethyl and the ethoxycarbonylmethyl group.
Halo-1-4C-alkoxy represents 1-4C-alkoxy groups which are completely or mainly substituted by halogen. "Mainly" in this connection means that more than half of the hydrogen atoms in the 1-4C-alkoxy groups are replaced by halogen atoms. Halo-1-4C-alkoxy groups are primarily chloro- and/or in particular fluoro-substituted 1-4C-alkoxy groups. Examples of halogen-sub-stituted 1-4C-alkoxy groups which may be mentioned are the 2,2,2-trichloroethoxy, the hexa-chloroisopropoxy, the pentachloroisopropoxy, the 1,1,1-trichloro-3,3,3-trifluoro-2-propoxy, the 1,1,1-trichloro-2-methyl-2-propoxy, the 1,1,1-trichloro-2-propoxy, the 3-bromo-1,1,1-trifluoro-2-propoxy, the 3-bromo-1,1,1-trifluoro-2-butoxy, the 4-bromo-3,3,4,4-tetrafluoro-1 -butoxy, the chlorodifluoromethoxy, the 1,1,1,3,3,3-hexafluoro-2-propoxy, the 2-trifluoromethyl-2-propoxy, the 1,1,1-trifluoro-2-propoxy, the perfluoro-tert-butoxy, the 2,2,3,3,4,4,4-heptafluoro-1 -butoxy, the 4,4,4-trifluoro-1 -butoxy, the 2,2,3,3,3-pentafluoropropoxy, the perfluoroethoxy, the 1,2,2-tri-fluoroethoxy, in particular the 1,1,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoro-methoxy and preferably the difluoromethoxy group.
Mono- or di-1 -4C-alkylamino represents an amino group, which is substituted by one or by two - identical or different - groups from the aforementioned 1-4C-alkyl groups.
Examples which may be mentioned are the dimethylamino, the diethylamino and the diisopropylamino group.
1-4C-Alkylcarbonyl represents a group, which in addition to the carbonyl group contains one of the aforementioned 1-4C-alkyl groups. An example which may be mentioned is the acetyl group.
1-4C-Alkylcarbonylamino represents an amino group to which a 1-4C-alkylcarbonyl group is bonded. Examples which may be mentioned are the propionylamino (C3H7C(O)NH-) and the acetylamino group (acetamido group) (CH3C(O)NH-) .
1-4C-Alkoxycarbonylamino represents an amino group, which is substituted by one of the aforementioned 1-4C-alkoxycarbonyl groups. Examples, which may be mentioned, are the eth-oxycarbonylamino and the methoxycarbonylamino group.
1-4C-Alkoxy-1-4C-alkoxycarbonyl represents a carbonyl group, to which one of the afore-mentioned 1-4C-alkoxy-1-4C-alkoxy groups is bonded. Examples which may be mentioned are the 2-(methoxy)ethoxycarbonyl (CH3-O-CHZCHZ-O-CO-) and the 2-(ethoxy)ethoxycarbonyl group (CH3CH2-O-CH2CH2-O-CO-).
1-4C-Alkoxy-1-4C-alkoxycarbonylamino represents an amino group, which is substituted by one of the aforementioned 1-4C-alkoxy-1-4C-alkoxycarbonyl groups. Examples which may be mentioned are the 2-(methoxy)ethoxycarbonylamino and the 2-(ethoxy)ethoxycarbonylamino group.
Hydroxypyrrolidino represents a pyrrolidino group, which is substituted by a hydroxy group.
Examples which may be mentioned are the 2-hydroxypyrrolidino and the 3-hydroxypyrrolidino groups.
Hydroxyazetidino represents an azetidino group, which is substituted by a hydroxy group. An which may be mentioned is the 3-hydroxyazetidino group.
Fluorazetidino represents an azetidino group, which is substituted by a fluoro atom. Examples which may be mentioned are the (2S)-and the (2R)-fluoroazetidino and in particular the 3-fluo-roazetidino group.
N-1-4C-alkylpiperazino represents a piperazino group, in which one of the piperazino nitrogen atoms is substituted by one of the aforementioned 1-4-C-alkyl groups. Examples which may be mentioned are the 4-methylpiperazino, the 4-ethylpiperazino and the 4-iso-propylpiperazino groups.
Possible salts of compounds of the formula 1- depending on substitution - are especially all acid addition salts. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids customarily used in pharmacy. Those suitable are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, malonic acid, fumaric acid, succinic acid, oxalic acid, tar-taric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, where the acids are used in salt preparation - depending on whether a mono- or polybasic acid is concerned and on which salt is desired - in an equimolar quantita-tive ratio or one differing therefrom.
Salts of the compounds of formula I according to the invention can be obtained by dissolving, the free compound in a suitable solvent (for example a ketone such as acetone, methylethylke-tone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or to which the desired acid is then added, if necessary upon heating. The acid can be employed in salt preparation, depending on whether a mono- or polybasic acid is concerned and depend-ing on which salt is desired, in an equimolar quantitative ratio or one differing therefrom. The salts are obtained for example by evaporating the solvent or by precipitating upon cooling, by re-precipitating, or by precipitating with a non-solvent for the salt and separation, for example by filtration, of the salt after precipitation.
Pharmacologically intolerable salts, which can initially be obtained, for example, as process products in the production of the compounds according to the invention on the industrial scale, are converted into the pharmacologically tolerable salts by processes known to the person skilled in the art.
N-1-4C-alkylpiperazino represents a piperazino group, in which one of the piperazino nitrogen atoms is substituted by one of the aforementioned 1-4-C-alkyl groups. Examples which may be mentioned are the 4-methylpiperazino, the 4-ethylpiperazino and the 4-iso-propylpiperazino groups.
Possible salts of compounds of the formula 1- depending on substitution - are especially all acid addition salts. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids customarily used in pharmacy. Those suitable are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, malonic acid, fumaric acid, succinic acid, oxalic acid, tar-taric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, where the acids are used in salt preparation - depending on whether a mono- or polybasic acid is concerned and on which salt is desired - in an equimolar quantita-tive ratio or one differing therefrom.
Salts of the compounds of formula I according to the invention can be obtained by dissolving, the free compound in a suitable solvent (for example a ketone such as acetone, methylethylke-tone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or to which the desired acid is then added, if necessary upon heating. The acid can be employed in salt preparation, depending on whether a mono- or polybasic acid is concerned and depend-ing on which salt is desired, in an equimolar quantitative ratio or one differing therefrom. The salts are obtained for example by evaporating the solvent or by precipitating upon cooling, by re-precipitating, or by precipitating with a non-solvent for the salt and separation, for example by filtration, of the salt after precipitation.
Pharmacologically intolerable salts, which can initially be obtained, for example, as process products in the production of the compounds according to the invention on the industrial scale, are converted into the pharmacologically tolerable salts by processes known to the person skilled in the art.
It is known to the person skilled in the art that the compounds according to the invention and their salts, if, for example, they are isolated in crystalline form, can contain various amounts of solvents. The invention therefore also comprises all solvates and in particular all hydrates of the compounds of the formula 1, and also all solvates and in particular all hydrates of the salts of the compounds of the formula 1.
The compounds of the formula 1 can have a center of chirality at the spiro carbon atom in 8-postion of the basic skeleton. The occurance of such a center of chirality depends on the na-ture and the position of the substituents R4 and R5. A center of chirality arises for example if R4 is different from R5. The invention thus relates to all feasible stereoisomers in any desired mixing ratio to another, including the pure stereoisomers, which are a preferred subject of the invention.
The invention therefore relates to all of the following stereoisomers of the formula 1:
N N N N
NH NH NH NH
(1 a) (1-b) (1-c) (1-d) R3 NR1 R3 N~R1 R3 F R1 R3 N-N N N N
NH NH NH
(1-e) (1-g) (1-h) The pure stereoisomers of the compounds of the formula 1 and salts according to the present invention can be obtained e.g. by asymmetric synthesis, by using chiral starting compounds in synthesis and by splitting up stereoisomeric mixtures obtained in synthesis.
Preferably, the pure stereoisomers of the compounds of the formula 1 are obtained by using chiral starting compounds.
Stereoisomeric mixtures of compounds of the formula 1 can be split up into the pure stereoi-somers by methods known to a person skilled in the art. Preferably, the mixtures are separated by chromatography or (fractional) crystallization. For enantiomeric mixtures the split up is pref-erably done by forming diastereomeric salts by adding chiral additives like chiral acids, subse-quent resolution of the salts and release of the desired compound from the salt. Alternatively, derivatization with chiral auxiliary reagents can be made, followed by diastereomer separation and removal of the chiral auxiliary group. Furthermore, enantiomeric mixtures can be sepa-rated using chiral separating columns in chromatography. Another suitable method for the separation of enantiomeric mixtures is the enzymatic separation.
One embodiment of the invention (embodiment 1) are compounds of the formula 1, in which R3 is hydrogen, and their salts.
Another embodiment of the invention (embodiment 2) are compounds of the formula 1, in which R3 is the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, and their salts.
Another embodiment of the invention (embodiment 3) are compounds of the formula 1, in which R3 is halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alk-oxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1 -4C-alkoxy-1 -4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl and their salts.
Another embodiment of the invention (embodiment 4) are compounds of the formula 1, in which R4 and R5 are each hydrogen, and their salts.
The compounds of the formula 1 can have a center of chirality at the spiro carbon atom in 8-postion of the basic skeleton. The occurance of such a center of chirality depends on the na-ture and the position of the substituents R4 and R5. A center of chirality arises for example if R4 is different from R5. The invention thus relates to all feasible stereoisomers in any desired mixing ratio to another, including the pure stereoisomers, which are a preferred subject of the invention.
The invention therefore relates to all of the following stereoisomers of the formula 1:
N N N N
NH NH NH NH
(1 a) (1-b) (1-c) (1-d) R3 NR1 R3 N~R1 R3 F R1 R3 N-N N N N
NH NH NH
(1-e) (1-g) (1-h) The pure stereoisomers of the compounds of the formula 1 and salts according to the present invention can be obtained e.g. by asymmetric synthesis, by using chiral starting compounds in synthesis and by splitting up stereoisomeric mixtures obtained in synthesis.
Preferably, the pure stereoisomers of the compounds of the formula 1 are obtained by using chiral starting compounds.
Stereoisomeric mixtures of compounds of the formula 1 can be split up into the pure stereoi-somers by methods known to a person skilled in the art. Preferably, the mixtures are separated by chromatography or (fractional) crystallization. For enantiomeric mixtures the split up is pref-erably done by forming diastereomeric salts by adding chiral additives like chiral acids, subse-quent resolution of the salts and release of the desired compound from the salt. Alternatively, derivatization with chiral auxiliary reagents can be made, followed by diastereomer separation and removal of the chiral auxiliary group. Furthermore, enantiomeric mixtures can be sepa-rated using chiral separating columns in chromatography. Another suitable method for the separation of enantiomeric mixtures is the enzymatic separation.
One embodiment of the invention (embodiment 1) are compounds of the formula 1, in which R3 is hydrogen, and their salts.
Another embodiment of the invention (embodiment 2) are compounds of the formula 1, in which R3 is the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, and their salts.
Another embodiment of the invention (embodiment 3) are compounds of the formula 1, in which R3 is halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alk-oxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1 -4C-alkoxy-1 -4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl and their salts.
Another embodiment of the invention (embodiment 4) are compounds of the formula 1, in which R4 and R5 are each hydrogen, and their salts.
Another embodiment of the invention (embodiment 5) are compounds of the formula 1, in which R1 is 1-4C-alkyl and their salts.
Another embodiment of the invention (embodiment 6) are compounds of the formula 1, in which R2 is hydrogen or 1-4C-alkyl, and their salts.
Another embodiment of the invention (embodiment 7) are compounds of the formula 1, in which R1 is methyl and their salts.
Another embodiment of the invention (embodiment 8) are compounds of the formula 1, in which R2 is hydrogen or methyl, and their salts.
An embodiment of the invention (embodiment 9) to be emphasized are compounds of the for-mula 1, in which R1 is methyl, R2 is hydrogen or methyl, and their salts.
The invention also relates to compounds of the formula 1, in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy- 1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hyd roxy- 1 -4C- al kyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1 -4C-alkyl, mono- or di-1-4C-alkylamino-1 -4C-alkyl or cyanomethyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-alkoxy-1 -4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, hydroxy-1-4C-alkoxy, 1-4C-alkoxy-1 -4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxyl, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1 -4C-alkyl, halogen, hydroxyl, trifluoromethyl, halo-1 -4C-alkoxy, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alkyl-carbonylamino, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1 -4C-alkoxycarbonylamino or sulfonyl, and their salts.
Compounds of the formula 1 which are to be mentioned are those, in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl or hydroxyl-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1 -4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl or fluoro-1 -4C-alkyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alk-oxy-1-4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1 -4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are also to be mentioned are those, in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-al kyl or hydroxyl-1-4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl or fluoro-1 -4C-alkyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1 -4C-alk-oxy-1 -4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are to be particularly mentioned are those, in which R1 is hydrogen, 1-4C-alkyl or hydroxy-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, hydroxy-1 -4C-alkyl or halogen, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1 -4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are also to be particularly mentioned are those, in which R1 is hydrogen, 1-4C-alkyl or hydroxy-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, hydroxy-1 -4C-alkyl or halogen, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are to be emphasized are those, in which R1 is 1-4C-alkyl, R2 is hydrogen or 1-4C-alkyl, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1 -4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are each hydrogen, and their salts.
Compounds of the formula 1 which are also to be emphasized are those, in which R1 is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl or the group -CO-NR31 R32 where R31 is 1-7C-alkyl and R32 is hydrogen, R4 and R5 are each hydrogen, and their salts.
Compounds of the formula 1 which are to particularly emphasized are those, in which R1 is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is hydrogen R4 and R5 are each hydrogen, and their salts.
Exemplary preferred compounds according to the invention are those compounds of the for-mula 1, wherein R1, R2, R3, R4 and R5 have the meanings as given in Table A
(Me = CH3, Et = C2H5), and the salts of these compounds. These compounds are either described by way of example as final products or can be prepared in an analogous manner using for example the process steps described below.
Table A:
Me Me CHZOH H H
Me Me CHZOCH3 H H
Me Me C(O)NHMe H H
Me Me C(O)N-pyrrolidine H H
Me Me C(O)NH(CH2)20H H H
Me Me C(O)NH(CH2)2OMe H H
Me Me C(O)NH2 H H
Me Me C(O)N-morpholine H H
Me Me C(O)NMe2 H H
Me Me C(O)N-aziridine H H
Me Me C(O)OEt H H
Me Me C(O)OH H H
Me Me C(O)N-azetidine H H
Me Me C(O)NH(CH2)2Me H H
Me Me C(O)NHCHZCH(OH)CHZOH H H
Me Me C(O)NH-cyclopropyl H H
Me Me H H H
Me Me C(O)NHEt H H
Me Me C(O)NH(CH2)30H H H
Another embodiment of the invention (embodiment 6) are compounds of the formula 1, in which R2 is hydrogen or 1-4C-alkyl, and their salts.
Another embodiment of the invention (embodiment 7) are compounds of the formula 1, in which R1 is methyl and their salts.
Another embodiment of the invention (embodiment 8) are compounds of the formula 1, in which R2 is hydrogen or methyl, and their salts.
An embodiment of the invention (embodiment 9) to be emphasized are compounds of the for-mula 1, in which R1 is methyl, R2 is hydrogen or methyl, and their salts.
The invention also relates to compounds of the formula 1, in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy- 1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hyd roxy- 1 -4C- al kyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1 -4C-alkyl, mono- or di-1-4C-alkylamino-1 -4C-alkyl or cyanomethyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-alkoxy-1 -4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, hydroxy-1-4C-alkoxy, 1-4C-alkoxy-1 -4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxyl, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1 -4C-alkyl, halogen, hydroxyl, trifluoromethyl, halo-1 -4C-alkoxy, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alkyl-carbonylamino, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1 -4C-alkoxycarbonylamino or sulfonyl, and their salts.
Compounds of the formula 1 which are to be mentioned are those, in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl or hydroxyl-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1 -4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl or fluoro-1 -4C-alkyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alk-oxy-1-4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1 -4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are also to be mentioned are those, in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-al kyl or hydroxyl-1-4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl or fluoro-1 -4C-alkyl, R3 is hydrogen, halogen, fluoro-1 -4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1 -4C-alk-oxy-1 -4C-alkyl, fluoro-1 -4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are to be particularly mentioned are those, in which R1 is hydrogen, 1-4C-alkyl or hydroxy-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, hydroxy-1 -4C-alkyl or halogen, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1 -4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1 -4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are also to be particularly mentioned are those, in which R1 is hydrogen, 1-4C-alkyl or hydroxy-1 -4C-alkyl, R2 is hydrogen, 1-4C-alkyl, hydroxy-1 -4C-alkyl or halogen, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and their salts.
Compounds of the formula 1 which are to be emphasized are those, in which R1 is 1-4C-alkyl, R2 is hydrogen or 1-4C-alkyl, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl or the group -CO-NR31 R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1 -4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1 -4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1 -4C-alkyl or 1-4C-alkoxy-1 -4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are each hydrogen, and their salts.
Compounds of the formula 1 which are also to be emphasized are those, in which R1 is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl or the group -CO-NR31 R32 where R31 is 1-7C-alkyl and R32 is hydrogen, R4 and R5 are each hydrogen, and their salts.
Compounds of the formula 1 which are to particularly emphasized are those, in which R1 is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is hydrogen R4 and R5 are each hydrogen, and their salts.
Exemplary preferred compounds according to the invention are those compounds of the for-mula 1, wherein R1, R2, R3, R4 and R5 have the meanings as given in Table A
(Me = CH3, Et = C2H5), and the salts of these compounds. These compounds are either described by way of example as final products or can be prepared in an analogous manner using for example the process steps described below.
Table A:
Me Me CHZOH H H
Me Me CHZOCH3 H H
Me Me C(O)NHMe H H
Me Me C(O)N-pyrrolidine H H
Me Me C(O)NH(CH2)20H H H
Me Me C(O)NH(CH2)2OMe H H
Me Me C(O)NH2 H H
Me Me C(O)N-morpholine H H
Me Me C(O)NMe2 H H
Me Me C(O)N-aziridine H H
Me Me C(O)OEt H H
Me Me C(O)OH H H
Me Me C(O)N-azetidine H H
Me Me C(O)NH(CH2)2Me H H
Me Me C(O)NHCHZCH(OH)CHZOH H H
Me Me C(O)NH-cyclopropyl H H
Me Me H H H
Me Me C(O)NHEt H H
Me Me C(O)NH(CH2)30H H H
Me Me C(O)NH(CH2)3OMe H H
Me Me C(O)NHCH2C(O)CH3 H H
Me Me C(O)N-3-fluorazetidine H H
Me Me C(O)N(CH3)-(CH2)20H H H
Me Me C(O)N(CH3)-(CH2)2OMe H H
Me Me C(O)N(CH3)-(CH2)30H H H
Me Me C(O)N(CH3)-(CH2)3OMe H H
Me H CHZOH H H
Me H CHZOCH3 H H
Me H C(O)NHMe H H
Me H C(O)N-pyrrolidine H H
Me H C(O)NH(CH2)20H H H
Me H C(O)NH(CH2)2OMe H H
Me H C(O)NH2 H H
Me H C(O)N-morpholine H H
Me H C(O)NMe2 H H
Me H C(O)N-aziridine H H
Me H C(O)OEt H H
Me H C(O)OH H H
Me H C(O)N-azetidine H H
Me H C(O)NH(CH2)2Me H H
Me H C(O)NHCHZCH(OH)CHZOH H H
Me H C(O)NH-cyclopropyl H H
Me H H H H
Me H C(O)NHEt H H
Me H C(O)NH(CH2)30H H H
Me H C(O)NH(CH2)3OMe H H
Me H C(O)NHCH2C(O)CH3 H H
Me H C(O)N-3-fluorazetidine H H
Me H C(O)N(CH3)-(CH2)20H H H
Me H C(O)N(CH3)-(CH2)2OMe H H
Me H C(O)N(CH3)-(CH2)30H H H
Me H C(O)N(CH3)-(CH2)3OMe H H
Exemplary particularly preferred compounds according to the invention are those described by way of example and the salts of these compounds.
Me Me C(O)NHCH2C(O)CH3 H H
Me Me C(O)N-3-fluorazetidine H H
Me Me C(O)N(CH3)-(CH2)20H H H
Me Me C(O)N(CH3)-(CH2)2OMe H H
Me Me C(O)N(CH3)-(CH2)30H H H
Me Me C(O)N(CH3)-(CH2)3OMe H H
Me H CHZOH H H
Me H CHZOCH3 H H
Me H C(O)NHMe H H
Me H C(O)N-pyrrolidine H H
Me H C(O)NH(CH2)20H H H
Me H C(O)NH(CH2)2OMe H H
Me H C(O)NH2 H H
Me H C(O)N-morpholine H H
Me H C(O)NMe2 H H
Me H C(O)N-aziridine H H
Me H C(O)OEt H H
Me H C(O)OH H H
Me H C(O)N-azetidine H H
Me H C(O)NH(CH2)2Me H H
Me H C(O)NHCHZCH(OH)CHZOH H H
Me H C(O)NH-cyclopropyl H H
Me H H H H
Me H C(O)NHEt H H
Me H C(O)NH(CH2)30H H H
Me H C(O)NH(CH2)3OMe H H
Me H C(O)NHCH2C(O)CH3 H H
Me H C(O)N-3-fluorazetidine H H
Me H C(O)N(CH3)-(CH2)20H H H
Me H C(O)N(CH3)-(CH2)2OMe H H
Me H C(O)N(CH3)-(CH2)30H H H
Me H C(O)N(CH3)-(CH2)3OMe H H
Exemplary particularly preferred compounds according to the invention are those described by way of example and the salts of these compounds.
The compounds according to the invention can be synthesized from corresponding starting compounds, for example according to the reaction schemes given below. The synthesis is car-ried out in a manner known to the expert, for example as described in more detail in the follow-ing examples.
As outlined in scheme 1, the compounds of the formula 1 can be obtained by reduction of the carbonyl group in the corresponding compounds of the formula 2 by methods which are famil-iar to a person skilled in the art, for example using triethylsilane /
trifluoroacetic acid (West et al., J. Org. Chem. 1973, 38, 2675-2681) or, for example using lithium aluminium hydride in the case when R3 is a group which can not be reduced under these conditions like for example R3 = hydrogen.
Scheme 1.
\ R1 R1 O N N
reduction NH (2) NH (1) Compounds of the formula 2 can be prepared for example as outlined in scheme 2. In a first step ketones of the formula 3 are reacted with spiro-amino acid derivatives of the formula 4 (wherein Y is a suitable leaving group, for example an 1-4C-alkoxy group, e.g.
an ethoxy group) to give compounds of the formula 5. In a second step, compounds of the formula 5 are oxidized by standard procedures using a suitable oxidizing agent (e.g.
chloranil or 2,3-dichloro-5,6-dicyanobenzoquinone) to give compounds of the formula 2.
Scheme 2.
As outlined in scheme 1, the compounds of the formula 1 can be obtained by reduction of the carbonyl group in the corresponding compounds of the formula 2 by methods which are famil-iar to a person skilled in the art, for example using triethylsilane /
trifluoroacetic acid (West et al., J. Org. Chem. 1973, 38, 2675-2681) or, for example using lithium aluminium hydride in the case when R3 is a group which can not be reduced under these conditions like for example R3 = hydrogen.
Scheme 1.
\ R1 R1 O N N
reduction NH (2) NH (1) Compounds of the formula 2 can be prepared for example as outlined in scheme 2. In a first step ketones of the formula 3 are reacted with spiro-amino acid derivatives of the formula 4 (wherein Y is a suitable leaving group, for example an 1-4C-alkoxy group, e.g.
an ethoxy group) to give compounds of the formula 5. In a second step, compounds of the formula 5 are oxidized by standard procedures using a suitable oxidizing agent (e.g.
chloranil or 2,3-dichloro-5,6-dicyanobenzoquinone) to give compounds of the formula 2.
Scheme 2.
R3 N NHz condensation N~ R1 ~ R1 + - O N
N
NH
O
oxidation N
O
N
NH
Ketones of the formula 3 are known to a person skilled in the art (inter alia from the Interna-tional Patent Applications WO 02/34749, WO 01 /72748, WO 01 /72757 or from Angew. Chem.
Int. Ed. Engl. 1996, 35, 545), or they can be prepared using analogous process steps which are known to a person skilled in the art.
As outlined in scheme 3, the required f3-amino acid derivatives of the general formula 4 can be prepared from the corresponding f3-hydroxy acids of the formula 5, wherein Y
is a suitable leaving group, for example an 1-4C-alkoxy group, e.g. an ethoxy group, by methods familiar to a person skilled in the art, like for example the Ritter reaction in analogy to the procedure de-scribed for example in Org. React. 1969, 17, 213. Compounds of the formula 5 are known to a person skilled in the art, for example from J. Chem. Soc. 1960, 4115, or they can be prepared using analogous process steps. If acetonitrile is used for the Ritter reaction, f3-amino acids of the formula 4* with PG = acetyl are obtained. The protecting group PG in compounds of the formula 4* can then be cleaved from the amino functionality by methods known to the expert, for example if PG is an acetyl group, it can be cleaved by acidic hydrolysis to give compounds of the formula 4. The group Y can be transformed into any other group Y by standard proce-dures known to the expert, for example by esterification.
Scheme 4:
N
NH
O
oxidation N
O
N
NH
Ketones of the formula 3 are known to a person skilled in the art (inter alia from the Interna-tional Patent Applications WO 02/34749, WO 01 /72748, WO 01 /72757 or from Angew. Chem.
Int. Ed. Engl. 1996, 35, 545), or they can be prepared using analogous process steps which are known to a person skilled in the art.
As outlined in scheme 3, the required f3-amino acid derivatives of the general formula 4 can be prepared from the corresponding f3-hydroxy acids of the formula 5, wherein Y
is a suitable leaving group, for example an 1-4C-alkoxy group, e.g. an ethoxy group, by methods familiar to a person skilled in the art, like for example the Ritter reaction in analogy to the procedure de-scribed for example in Org. React. 1969, 17, 213. Compounds of the formula 5 are known to a person skilled in the art, for example from J. Chem. Soc. 1960, 4115, or they can be prepared using analogous process steps. If acetonitrile is used for the Ritter reaction, f3-amino acids of the formula 4* with PG = acetyl are obtained. The protecting group PG in compounds of the formula 4* can then be cleaved from the amino functionality by methods known to the expert, for example if PG is an acetyl group, it can be cleaved by acidic hydrolysis to give compounds of the formula 4. The group Y can be transformed into any other group Y by standard proce-dures known to the expert, for example by esterification.
Scheme 4:
O Y O Y O Y
PG
Ritter reaction Deprotection 4' 4 The derivatization, if any, of the compounds obtained according to the schemes above (e.g.
conversion of a group R3 into another group R3 or conversion of a hydroxyl group into an alkoxy or ester group) is likewise carried out in a manner known per se. If, for example, com-pounds of the formula 1 where R3 = -CO-NR31 R32 are desired, an appropriate derivatization can be performed in a manner known per se (e. g. conversion of an ester or a carboxylic acid into an amide), preferably at the stage of compounds of the formula 1 or at the stage of any in-termediate thereof.
The reaction steps outlined above are carried out in a manner known per se, e.g. as described in more detail in the examples.
The present invention further relates to compounds of the formula 2 and 5 shown above, which are intermediates in the process of producing the compounds of the formula 1 according to the present invention. R1, R2, R3, R4, R5 are thereby defined as for compounds of the formula 1.
The person skilled in the art knows on the basis of his/her knowledge and on the basis of those synthesis routes, which are shown and described within the description of this invention, how to find other possible synthesis routes for compounds according to this invention. All synthesis routes described herein as well as all other possible synthesis routes are also part of this in-vention.
PG
Ritter reaction Deprotection 4' 4 The derivatization, if any, of the compounds obtained according to the schemes above (e.g.
conversion of a group R3 into another group R3 or conversion of a hydroxyl group into an alkoxy or ester group) is likewise carried out in a manner known per se. If, for example, com-pounds of the formula 1 where R3 = -CO-NR31 R32 are desired, an appropriate derivatization can be performed in a manner known per se (e. g. conversion of an ester or a carboxylic acid into an amide), preferably at the stage of compounds of the formula 1 or at the stage of any in-termediate thereof.
The reaction steps outlined above are carried out in a manner known per se, e.g. as described in more detail in the examples.
The present invention further relates to compounds of the formula 2 and 5 shown above, which are intermediates in the process of producing the compounds of the formula 1 according to the present invention. R1, R2, R3, R4, R5 are thereby defined as for compounds of the formula 1.
The person skilled in the art knows on the basis of his/her knowledge and on the basis of those synthesis routes, which are shown and described within the description of this invention, how to find other possible synthesis routes for compounds according to this invention. All synthesis routes described herein as well as all other possible synthesis routes are also part of this in-vention.
Advantageous effects The excellent gastric protective action and the gastric acid secretion-inhibiting action of the compounds according to the invention can be demonstrated in investigations on animal ex-perimental models. The compounds of the formula 1 according to the invention investigated in the model mentioned below have been provided with numbers which correspond to the num-bers of these compounds in the examples.
Testing of the secretion-inhibiting action on the perfused rat stomach In Table A which follows, the influence of the compounds of the formula 1 according to the in-vention on the pentagastrin-stimulated acid secretion of the perfused rat stomach after intra-duodenal administration in vivo is shown.
Table A
Dose Inhibition of No. ( mol/kg) acid secretion i.d. (%) 1 1 > 40 Methodology The abdomen of anesthetized rats (CD rat, female, 200-250 g; 1.5 g/kg i.m.
urethane) was opened after tracheotomy by a median upper abdominal incision and a PVC
catheter was fixed transorally in the esophagus and another via the pylorus such that the ends of the tubes just projected into the gastric lumen. The catheter leading from the pylorus led outward into the right abdominal wall through a side opening.
After thorough rinsing (about 50-100 ml), warm (37 C) physiological NaCI
solution was con-tinuously passed through the stomach (0.5 ml/min, pH 6.8-6.9; Braun-Unita I).
The pH (pH me-ter 632, glass electrode EA 147; ~= 5 mm, Metrohm) and, by titration with a freshly prepared 0.01 N NaOH solution to pH 7 (Dosimat 665 Metrohm), the secreted HCI were determined in the effluent in each case collected at an interval of 15 minutes.
The gastric secretion was stimulated by continuous infusion of 1 g/kg (= 1.65 ml/h) of i.v. pen-tagastrin (left femoral vein) about 30 min after the end of the operation (i.e. after determination of 2 preliminary fractions). The substances to be tested were administered intraduodenally in a 2.5 ml/kg liquid volume 60 min after the start of the continuous pentagastrin infusion. The body temperature of the animals was kept at a constant 37.8-38 C by infrared irradiation and heat pads (automatic, stepless control by means of a rectal temperature sensor).
Mode(s) for Carrying Out the Invention The following examples serve to illustrate the invention in greater detail without restricting it. Likewise, further compounds of the formula 1 whose preparation is not described explicitly can be prepared in an analogous manner or in a manner familiar per se to the person skilled in the art using customary proc-ess techniques. The abbreviation min stands for minute(s), h for hour(s) and m.p. for melting point.
1. Final Compounds of the formula 1 1. 2,3-Di met hyl-1',3',7,10-tetrahyd ro-8H-sp i ro [i m id azo [ 1,2-h]-1,7-n ap hthyrid i ne-9,2'-i ndene]
To a suspension of 0.7 g (2.2 mmol) 2,3-dimethyl-1',3'-dihydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyri-dine-9,2'-inden]-7(1 oH)-one in 12 ml tetrahydrofuran were slowly added 4.4 ml (4.4 mmol) lithium alu-minium hydride (1 M in diethyl ether) at 0 C. After 2 h, the reaction mixture was hydrolyzed with 0.17 ml water, 0.2 ml aqueous sodium hydroxide (10 %) and 0.5 ml water. Anhydrous magnesium sulphate was added and the mixture was filtered. The filtrate was evaporated and the residue purified by column chromatography (silica gel, ethyl acetate). Crystallization from ethyl acetate/diethyl ether yielded 270 mg (40 %) of the title compound as a colourless solid. m.p. 175-176 C.
2. Methyl 2,3-dimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate To a solution of 0.42 g (1.12 mmol) methyl 2,3-dimethyl-7-oxo-1',3',7,10-tetrahydro-8H-spiro[imida-zo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate in 5.5 ml trifluoroacetic acid were added 1.1 ml (6.9 mmol) triethylsilane and the mixture was stirred overnight at 40 C. A
further amount of 0.3 ml triethylsilane was added and stirring was continued for 24 h at 40 C. The reaction mixture was evapo-rated, neutralized with saturated aqueous sodium hydrogen carbonate and extracted with ethyl ace-tate. The organic layer was separated, dried over anhydrous magnesium sulphate and concentrated in vacuo. Purification of the residue by column chromatography (silica gel, ethyl acetate/petroleum ether/triethylamine 2:8:1) and crystallization from ethyl acetate/n-heptane yielded 0.34 g (84 %) of the title compound as a near colourless solid. m.p. 188-189 C.
3. 2,3-Di met hyl-1',3',7,10-tetrahyd ro-8H-sp i ro [i m id azo [ 1,2-h] -1,7-n ap hthyrid i ne-9,2'-i ndene]-6-carboxylic acid A solution of 150 mg (0.42 mmol) methyl 2,3-dimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate and 415 mg (3.7 mmol) potassium tert-butoxide in 15 ml tert-butanol was heated to 50 C. After 1 h, the mixture was evaporated to dryness, dissolved in 2 ml water and neutralized with 10% hydrochloric acid. The precipitate was collected and dried in vacuo over phosphorus pentoxide to yield 105 mg (72 %) of the title compound as a beige solid. m.p. >300 OC.
4. N,2,3-Trimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxamide To a suspension of 90 mg (0.26 mmol) 2,3-dimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylic acid in 4 ml tetrahydrofuran were added 1.04 g (6.4 mmol) N,N'-carbonyldiimidazole and the mixture was heated to reflux. After 6 h, 0.5 ml (3.5 mmol) methyl-amine (7M in N,N-dimethylformamide) were added at 0 C. After 30 min, the reaction mixture was par-titioned between saturated aqueous ammonium chloride and dichloromethane. The organic layer was washed with saturated aqueous sodium hydrogen carbonate, dried over anhydrous magnesium sul-phate and evaporated. The residue was crystallized from ethyl acetate/heptane to yield 39 mg (42 %) of the title compound as a colourless solid. m.p. 157-158 C.
II. Starting Compounds A. 2,3-Di methyl-1',3',6,10-tetrahyd ro-5H-sp i ro [i m id azo [ 1,2-h]-1,7-n ap hthyrid i ne-9,2'-i nden]-7(8H)-one A mixture of 3.8 g (17 mmol) ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate, [liberated from its hy-drochloride salt, ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate hydrochloride, example K, by treat-ment with triethylamine], 3.2 g (20 mmol) 2,3-dimethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine and 200 mg p-toluenesulphonic acid monohydrate in 80 ml xylene was heated under reflux for 16 h while water was removed with a Dean-Stark trap. The reaction mixture was cooled to room tempera-ture and diluted with 80 ml tetrahydrofuran. At -40 C, 25 ml (25 mmol) of lithium bis(trimethylsilylamide) (1 M in tetrahydrofuran) were added dropwise during 5 min and the mixture was allowed to warm to room temperature. The reaction mixture was hydrolyzed with 60 ml saturated aque-ous ammonium chloride and extracted with dichloromethane. The organic layer was separated and dried over anhydrous sodium sulphate. On concentration in vacuo, a precipitate formed which was collected and rinsed with xylene and heptane to yield 3.0 g (55 %) of the title compound as a yellow solid. m.p. 232-233 C.
B. 2,3-Dimethyl-1',3'-dihydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-inden]-7(1 oH)-one To a solution of 3.0 g (9.4 mmol) 2,3-dimethyl-1',3',6,10-tetrahydro-5H-spiro[imidazo[1,2-h]-1,7-naph-thyridine-9,2'-inden]-7(8H)-one in 50 ml dichloromethane were added 2.56 g(11.3 mmol) 2,3-dichloro-5,6-dicyanobenzoquinone at 0 C and the mixture was allowed to warm to room temperature. After 2 h, additional 2,3-dichloro-5,6-dicyanobenzoquinone (0.3 g, 1.4 mmol) was added and the mixture was stirred overnight. The mixture was diluted with 500 ml dichloromethane and washed with 1 N aqueous sodium hydroxide (3 x 500 ml). The organic layer was separated, dried over anhydrous sodium sul-phate and concentrated in vacuo. Purification of the residue by column chromatography (silica gel, ethyl acetate) yielded 0.9 g (30 %) of the title compound as a yellow solid.
m.p. 288-290 C.
C. Methyl 2,3-dimethyl-7-oxo-1',3',6,7,8,10-hexahydro-5H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate A mixture of 9.0 g (41 mmol) ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate, [liberated from its hy-drochloride salt, ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate hydrochloride, example K, by treat-ment with triethylamine], 7.63 g (34.3 mmol) methyl 2,3-dimethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate and 250 mg p-toluenesulphonic acid monohydrate in 250 ml degassed xylene was heated under reflux for 3 d while water was removed with a Dean-Stark trap. The reaction mixture was cooled to room temperature and evaporated. The residue was purified by column chromatography (silica gel, ethyl acetate) and crystallized from ethyl acetate/n-heptane to yield 1.3 g (10 %) of the title compound as a yellow solid. m.p. 185-186 C.
D. Methyl 2,3-dimethyl-7-oxo-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate 1.3 g (3.44 mmol) methyl 2,3-dimethyl-7-oxo-1',3',6,7,8,10-hexahydro-5H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate were dissolved in 100 ml ethyl acetate at 45-50 C. To this solution were added 7.8 g (34.4 mmol) 2,3-dichloro-5,6-dicyanobenzoquinone portionwise over a pe-riod of 6 h at room temperature. To the reaction mixture were added 200 ml water and 50 ml 2N aque-ous potassium hydroxide. The mixture was extracted with ethyl acetate and the organic layer was washed with saturated aqueous sodium hydrogen carbonate. The organic layer was dried over anhy-drous magnesium sulphate and concentrated in vacuo. Purification of the residue by column chroma-tography (silica gel, ethyl acetate) and crystallization from ethyl acetate/n-heptane yielded 0.49 g (38 %) of the title compound as a light green solid.'H-NMR (CDC13): 2.34 (s, 3 H, CH3), 2.36 (s, 3 H, CH3), 2.92 (m, 2 H), 3.24 (s, 4 H), 3.95 (s, 3 H, OCH3), 6.22 (bs, 1 H, NH), 7.19 (m, 4 H), 7.31 (s, 1 H).
E. 8-(Benzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid To a solution of 6.5 g ethyl 8-(benzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate in 200 ml dioxane are added 15 ml 6N aqueous sodium hydroxide and the mixture is heated to 100 C. After 20 min, 200 ml water and 35 ml 4N hydrochloric acid are added to give a suspension which is stirred for 15 min. The precipitate is collected, washed with water and dried in vacuo to give 5.47 g (92 %) of the title compound as a colourless solid of melting point 191-193 C.
F. Methyl 8-hydroxy-2,3-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate A solution of 139.6 g 8-(benzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid is hydrogen-ated over 20 g palladium on charcoal (80-100 bar, 80 C). After complete reaction, the catalyst is fil-tered off and the filtrate is evaporated to give a solid which is suspended in 500 ml methanol. This sus-pension is added to a solution of 41 ml thionyl chloride in 500 ml methanol at 0 C. After 30 min at room temperature, the mixture is heated to 60 C for 4 h. The solvent is evaporated and the residue partitioned between dichloromethane and saturated aqueous sodium hydrogencarbonate. The organic layer is separated, dried over anhydrous magnesium sulphate and evaporated to give 71.4 g (78 %) of the title compound as a colourless solid (95 % purity, melting point 186-187 C).
G. Methyl 2,3-dimethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate To a solution of 0.22 g methyl 8-hydroxy-2,3-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carb-oxylate in 10 ml chloroform are added 0.9 g manganese(IV) oxide. After 9 h, the mixture is filtered through celite and the filtrate is evaporated. The residue is triturated with diisopropyl ether to give 0.16 g (72 %) of the title compound of melting point 156-157 C.
H. Ethyl (2-hydroxy-2,3-dihydro-1 H-inden-2-yl)acetate A solution of lithium diisopropylamide in heptane/tetrahydrofuran (305 ml, 0.55 mol) was cooled to -75 C and 55 ml (0.56 mol) ethyl acetate were added dropwise while the temperature was kept below -75 C. After addition was complete, the mixture was stirred at -75 C for 30 min.
A solution of 36.5 g (0.27 mol) 2-indanone in 90 ml tetrahydrofuran was added dropwise while the temperature was kept below -75 C. The mixture was stirred for 60 min while the temperature was allowed to rise to -12 C. The mixture was quenched with 200 ml tetrahydrofuran/water (1:1) and 500 ml saturated aqueous ammo-nium chloride solution were added. The mixture was acidified with 5N
hydrochloric acid and extracted with tert-butyl methyl ether (2 x 500 ml). The organic layer was dried over anhydrous sodium sulphate and concentrated in vacuo. The residue was purified by distillation at 123-130 C and 0.5 mm Hg, af-fording 31.2 g (52 %) of the title compound.'H-NMR (CDCI3): 1.30 (t, J = 7.1 Hz, 3 H), 2.76 (s, 2 H), 3.02 (d, J = 16.1 Hz, 2 H), 3.15 (d, J = 16.1 Hz, 2 H), 3.71 (s, 1 H, OH), 4.21 (q, J = 7.1 Hz, 2 H), 7.18 (m, 4 H).
1. Ethyl [2-(acetylamino)-2,3-dihydro-1 H-inden-2-yl]-acetate A solution of 75 g (0.34 mol) ethyl (2-hydroxy-2,3-dihydro-1 H-inden-2-yl)acetate in 1.5 L acetonitrile was cooled to 5 C. 67 ml chlorosulphonic acid were added dropwise while the temperature was al-lowed to rise to 14 C. The reaction mixture was then stirred for 5 h at ambient temperature. The mix-ture was poured into water (10 L) and extracted with ethyl acetate. The organic layer was concentrated in vacuo affording 47.7 g (54 %) of the title compound. m.p. 72-73 C.
J. (2-Amino-2,3-dihydro-1 H-inden-2-yl)acetic acid hydrochloride A solution of 23.5 g (90 mmol) ethyl [2-(acetylamino)-2,3-dihydro-1 H-inden-2-yl]-acetate in 200 ml 5N
hydrochloric acid was refluxed overnight. The mixture was evaporated to dryness and the residue was mixed with ethyl acetate. The obtained solid was collected by filtration affording 12.4 g (61 %) of the title compound. m.p. 176-178 C.
K. Ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate hydrochloride A solution of 12.4 g (55 mmol) (2-amino-2,3-dihydro-1 H-inden-2-yl)acetic acid hydrochloride in 250 ml ethanol was cooled to 0-5 C and 7.5 ml thionylchloride were added dropwise during 20 min. The mix-ture was refluxed for 3 h and concentrated in vacuo affording 17 g (quant.) of the title compound. m.p.
188-190 C.
Testing of the secretion-inhibiting action on the perfused rat stomach In Table A which follows, the influence of the compounds of the formula 1 according to the in-vention on the pentagastrin-stimulated acid secretion of the perfused rat stomach after intra-duodenal administration in vivo is shown.
Table A
Dose Inhibition of No. ( mol/kg) acid secretion i.d. (%) 1 1 > 40 Methodology The abdomen of anesthetized rats (CD rat, female, 200-250 g; 1.5 g/kg i.m.
urethane) was opened after tracheotomy by a median upper abdominal incision and a PVC
catheter was fixed transorally in the esophagus and another via the pylorus such that the ends of the tubes just projected into the gastric lumen. The catheter leading from the pylorus led outward into the right abdominal wall through a side opening.
After thorough rinsing (about 50-100 ml), warm (37 C) physiological NaCI
solution was con-tinuously passed through the stomach (0.5 ml/min, pH 6.8-6.9; Braun-Unita I).
The pH (pH me-ter 632, glass electrode EA 147; ~= 5 mm, Metrohm) and, by titration with a freshly prepared 0.01 N NaOH solution to pH 7 (Dosimat 665 Metrohm), the secreted HCI were determined in the effluent in each case collected at an interval of 15 minutes.
The gastric secretion was stimulated by continuous infusion of 1 g/kg (= 1.65 ml/h) of i.v. pen-tagastrin (left femoral vein) about 30 min after the end of the operation (i.e. after determination of 2 preliminary fractions). The substances to be tested were administered intraduodenally in a 2.5 ml/kg liquid volume 60 min after the start of the continuous pentagastrin infusion. The body temperature of the animals was kept at a constant 37.8-38 C by infrared irradiation and heat pads (automatic, stepless control by means of a rectal temperature sensor).
Mode(s) for Carrying Out the Invention The following examples serve to illustrate the invention in greater detail without restricting it. Likewise, further compounds of the formula 1 whose preparation is not described explicitly can be prepared in an analogous manner or in a manner familiar per se to the person skilled in the art using customary proc-ess techniques. The abbreviation min stands for minute(s), h for hour(s) and m.p. for melting point.
1. Final Compounds of the formula 1 1. 2,3-Di met hyl-1',3',7,10-tetrahyd ro-8H-sp i ro [i m id azo [ 1,2-h]-1,7-n ap hthyrid i ne-9,2'-i ndene]
To a suspension of 0.7 g (2.2 mmol) 2,3-dimethyl-1',3'-dihydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyri-dine-9,2'-inden]-7(1 oH)-one in 12 ml tetrahydrofuran were slowly added 4.4 ml (4.4 mmol) lithium alu-minium hydride (1 M in diethyl ether) at 0 C. After 2 h, the reaction mixture was hydrolyzed with 0.17 ml water, 0.2 ml aqueous sodium hydroxide (10 %) and 0.5 ml water. Anhydrous magnesium sulphate was added and the mixture was filtered. The filtrate was evaporated and the residue purified by column chromatography (silica gel, ethyl acetate). Crystallization from ethyl acetate/diethyl ether yielded 270 mg (40 %) of the title compound as a colourless solid. m.p. 175-176 C.
2. Methyl 2,3-dimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate To a solution of 0.42 g (1.12 mmol) methyl 2,3-dimethyl-7-oxo-1',3',7,10-tetrahydro-8H-spiro[imida-zo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate in 5.5 ml trifluoroacetic acid were added 1.1 ml (6.9 mmol) triethylsilane and the mixture was stirred overnight at 40 C. A
further amount of 0.3 ml triethylsilane was added and stirring was continued for 24 h at 40 C. The reaction mixture was evapo-rated, neutralized with saturated aqueous sodium hydrogen carbonate and extracted with ethyl ace-tate. The organic layer was separated, dried over anhydrous magnesium sulphate and concentrated in vacuo. Purification of the residue by column chromatography (silica gel, ethyl acetate/petroleum ether/triethylamine 2:8:1) and crystallization from ethyl acetate/n-heptane yielded 0.34 g (84 %) of the title compound as a near colourless solid. m.p. 188-189 C.
3. 2,3-Di met hyl-1',3',7,10-tetrahyd ro-8H-sp i ro [i m id azo [ 1,2-h] -1,7-n ap hthyrid i ne-9,2'-i ndene]-6-carboxylic acid A solution of 150 mg (0.42 mmol) methyl 2,3-dimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate and 415 mg (3.7 mmol) potassium tert-butoxide in 15 ml tert-butanol was heated to 50 C. After 1 h, the mixture was evaporated to dryness, dissolved in 2 ml water and neutralized with 10% hydrochloric acid. The precipitate was collected and dried in vacuo over phosphorus pentoxide to yield 105 mg (72 %) of the title compound as a beige solid. m.p. >300 OC.
4. N,2,3-Trimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxamide To a suspension of 90 mg (0.26 mmol) 2,3-dimethyl-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylic acid in 4 ml tetrahydrofuran were added 1.04 g (6.4 mmol) N,N'-carbonyldiimidazole and the mixture was heated to reflux. After 6 h, 0.5 ml (3.5 mmol) methyl-amine (7M in N,N-dimethylformamide) were added at 0 C. After 30 min, the reaction mixture was par-titioned between saturated aqueous ammonium chloride and dichloromethane. The organic layer was washed with saturated aqueous sodium hydrogen carbonate, dried over anhydrous magnesium sul-phate and evaporated. The residue was crystallized from ethyl acetate/heptane to yield 39 mg (42 %) of the title compound as a colourless solid. m.p. 157-158 C.
II. Starting Compounds A. 2,3-Di methyl-1',3',6,10-tetrahyd ro-5H-sp i ro [i m id azo [ 1,2-h]-1,7-n ap hthyrid i ne-9,2'-i nden]-7(8H)-one A mixture of 3.8 g (17 mmol) ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate, [liberated from its hy-drochloride salt, ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate hydrochloride, example K, by treat-ment with triethylamine], 3.2 g (20 mmol) 2,3-dimethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine and 200 mg p-toluenesulphonic acid monohydrate in 80 ml xylene was heated under reflux for 16 h while water was removed with a Dean-Stark trap. The reaction mixture was cooled to room tempera-ture and diluted with 80 ml tetrahydrofuran. At -40 C, 25 ml (25 mmol) of lithium bis(trimethylsilylamide) (1 M in tetrahydrofuran) were added dropwise during 5 min and the mixture was allowed to warm to room temperature. The reaction mixture was hydrolyzed with 60 ml saturated aque-ous ammonium chloride and extracted with dichloromethane. The organic layer was separated and dried over anhydrous sodium sulphate. On concentration in vacuo, a precipitate formed which was collected and rinsed with xylene and heptane to yield 3.0 g (55 %) of the title compound as a yellow solid. m.p. 232-233 C.
B. 2,3-Dimethyl-1',3'-dihydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-inden]-7(1 oH)-one To a solution of 3.0 g (9.4 mmol) 2,3-dimethyl-1',3',6,10-tetrahydro-5H-spiro[imidazo[1,2-h]-1,7-naph-thyridine-9,2'-inden]-7(8H)-one in 50 ml dichloromethane were added 2.56 g(11.3 mmol) 2,3-dichloro-5,6-dicyanobenzoquinone at 0 C and the mixture was allowed to warm to room temperature. After 2 h, additional 2,3-dichloro-5,6-dicyanobenzoquinone (0.3 g, 1.4 mmol) was added and the mixture was stirred overnight. The mixture was diluted with 500 ml dichloromethane and washed with 1 N aqueous sodium hydroxide (3 x 500 ml). The organic layer was separated, dried over anhydrous sodium sul-phate and concentrated in vacuo. Purification of the residue by column chromatography (silica gel, ethyl acetate) yielded 0.9 g (30 %) of the title compound as a yellow solid.
m.p. 288-290 C.
C. Methyl 2,3-dimethyl-7-oxo-1',3',6,7,8,10-hexahydro-5H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate A mixture of 9.0 g (41 mmol) ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate, [liberated from its hy-drochloride salt, ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate hydrochloride, example K, by treat-ment with triethylamine], 7.63 g (34.3 mmol) methyl 2,3-dimethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate and 250 mg p-toluenesulphonic acid monohydrate in 250 ml degassed xylene was heated under reflux for 3 d while water was removed with a Dean-Stark trap. The reaction mixture was cooled to room temperature and evaporated. The residue was purified by column chromatography (silica gel, ethyl acetate) and crystallized from ethyl acetate/n-heptane to yield 1.3 g (10 %) of the title compound as a yellow solid. m.p. 185-186 C.
D. Methyl 2,3-dimethyl-7-oxo-1',3',7,10-tetrahydro-8H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate 1.3 g (3.44 mmol) methyl 2,3-dimethyl-7-oxo-1',3',6,7,8,10-hexahydro-5H-spiro[imidazo[1,2-h]-1,7-naphthyridine-9,2'-indene]-6-carboxylate were dissolved in 100 ml ethyl acetate at 45-50 C. To this solution were added 7.8 g (34.4 mmol) 2,3-dichloro-5,6-dicyanobenzoquinone portionwise over a pe-riod of 6 h at room temperature. To the reaction mixture were added 200 ml water and 50 ml 2N aque-ous potassium hydroxide. The mixture was extracted with ethyl acetate and the organic layer was washed with saturated aqueous sodium hydrogen carbonate. The organic layer was dried over anhy-drous magnesium sulphate and concentrated in vacuo. Purification of the residue by column chroma-tography (silica gel, ethyl acetate) and crystallization from ethyl acetate/n-heptane yielded 0.49 g (38 %) of the title compound as a light green solid.'H-NMR (CDC13): 2.34 (s, 3 H, CH3), 2.36 (s, 3 H, CH3), 2.92 (m, 2 H), 3.24 (s, 4 H), 3.95 (s, 3 H, OCH3), 6.22 (bs, 1 H, NH), 7.19 (m, 4 H), 7.31 (s, 1 H).
E. 8-(Benzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid To a solution of 6.5 g ethyl 8-(benzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate in 200 ml dioxane are added 15 ml 6N aqueous sodium hydroxide and the mixture is heated to 100 C. After 20 min, 200 ml water and 35 ml 4N hydrochloric acid are added to give a suspension which is stirred for 15 min. The precipitate is collected, washed with water and dried in vacuo to give 5.47 g (92 %) of the title compound as a colourless solid of melting point 191-193 C.
F. Methyl 8-hydroxy-2,3-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate A solution of 139.6 g 8-(benzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid is hydrogen-ated over 20 g palladium on charcoal (80-100 bar, 80 C). After complete reaction, the catalyst is fil-tered off and the filtrate is evaporated to give a solid which is suspended in 500 ml methanol. This sus-pension is added to a solution of 41 ml thionyl chloride in 500 ml methanol at 0 C. After 30 min at room temperature, the mixture is heated to 60 C for 4 h. The solvent is evaporated and the residue partitioned between dichloromethane and saturated aqueous sodium hydrogencarbonate. The organic layer is separated, dried over anhydrous magnesium sulphate and evaporated to give 71.4 g (78 %) of the title compound as a colourless solid (95 % purity, melting point 186-187 C).
G. Methyl 2,3-dimethyl-8-oxo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate To a solution of 0.22 g methyl 8-hydroxy-2,3-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carb-oxylate in 10 ml chloroform are added 0.9 g manganese(IV) oxide. After 9 h, the mixture is filtered through celite and the filtrate is evaporated. The residue is triturated with diisopropyl ether to give 0.16 g (72 %) of the title compound of melting point 156-157 C.
H. Ethyl (2-hydroxy-2,3-dihydro-1 H-inden-2-yl)acetate A solution of lithium diisopropylamide in heptane/tetrahydrofuran (305 ml, 0.55 mol) was cooled to -75 C and 55 ml (0.56 mol) ethyl acetate were added dropwise while the temperature was kept below -75 C. After addition was complete, the mixture was stirred at -75 C for 30 min.
A solution of 36.5 g (0.27 mol) 2-indanone in 90 ml tetrahydrofuran was added dropwise while the temperature was kept below -75 C. The mixture was stirred for 60 min while the temperature was allowed to rise to -12 C. The mixture was quenched with 200 ml tetrahydrofuran/water (1:1) and 500 ml saturated aqueous ammo-nium chloride solution were added. The mixture was acidified with 5N
hydrochloric acid and extracted with tert-butyl methyl ether (2 x 500 ml). The organic layer was dried over anhydrous sodium sulphate and concentrated in vacuo. The residue was purified by distillation at 123-130 C and 0.5 mm Hg, af-fording 31.2 g (52 %) of the title compound.'H-NMR (CDCI3): 1.30 (t, J = 7.1 Hz, 3 H), 2.76 (s, 2 H), 3.02 (d, J = 16.1 Hz, 2 H), 3.15 (d, J = 16.1 Hz, 2 H), 3.71 (s, 1 H, OH), 4.21 (q, J = 7.1 Hz, 2 H), 7.18 (m, 4 H).
1. Ethyl [2-(acetylamino)-2,3-dihydro-1 H-inden-2-yl]-acetate A solution of 75 g (0.34 mol) ethyl (2-hydroxy-2,3-dihydro-1 H-inden-2-yl)acetate in 1.5 L acetonitrile was cooled to 5 C. 67 ml chlorosulphonic acid were added dropwise while the temperature was al-lowed to rise to 14 C. The reaction mixture was then stirred for 5 h at ambient temperature. The mix-ture was poured into water (10 L) and extracted with ethyl acetate. The organic layer was concentrated in vacuo affording 47.7 g (54 %) of the title compound. m.p. 72-73 C.
J. (2-Amino-2,3-dihydro-1 H-inden-2-yl)acetic acid hydrochloride A solution of 23.5 g (90 mmol) ethyl [2-(acetylamino)-2,3-dihydro-1 H-inden-2-yl]-acetate in 200 ml 5N
hydrochloric acid was refluxed overnight. The mixture was evaporated to dryness and the residue was mixed with ethyl acetate. The obtained solid was collected by filtration affording 12.4 g (61 %) of the title compound. m.p. 176-178 C.
K. Ethyl (2-amino-2,3-dihydro-1 H-inden-2-yl)acetate hydrochloride A solution of 12.4 g (55 mmol) (2-amino-2,3-dihydro-1 H-inden-2-yl)acetic acid hydrochloride in 250 ml ethanol was cooled to 0-5 C and 7.5 ml thionylchloride were added dropwise during 20 min. The mix-ture was refluxed for 3 h and concentrated in vacuo affording 17 g (quant.) of the title compound. m.p.
188-190 C.
Industrial applicability The compounds of the formula 1 and their pharmaceutically acceptable salts (=
active compounds according to the invention) have valuable pharmacological properties which make them commer-cially utilizable. In particular, they exhibit marked inhibition of gastric acid secretion and an excellent gastric and intestinal protective or curative action in warm-blooded animals, in particular humans. In this connection, the active compounds according to the invention are distinguished by a high selec-tivity of action, a fast onset of action, an advantageous duration of action, efficient control of the du-ration of action by the dosage, a particularly good antisecretory efficacy, the absence of significant side effects and a large therapeutic range.
"Gastric and intestinal protection or cure" in this connection is understood to include, according to general knowledge, the prevention, the treatment and the maintenance treatment of gastrointestinal diseases, in particular of gastrointestinal inflammatory diseases and lesions (such as, for example, reflux esophagitis, gastritis, hyperacidic or drug-related functional dyspepsia, and peptic ulcer dis-ease [including peptic ulcer bleeding, gastric ulcer, duodenal ulcer]), which can be caused, for ex-ample, by microorganisms (e.g. Helicobacter pylori), bacterial toxins, drugs (e.g. certain antiinflam-matories and antirheumatics, such as NSAIDs and COX-inhibitors), chemicals (e.g. ethanol), gas-tric acid or stress situations.
The term "gastrointestinal diseases" is understood to include, according to general knowledge, A) gastroesophageal reflux disease (GERD), the symptoms of which include, but are not limited to, heartburn and/or acid regurgitation and/or non-acid regurgitation.
B) other extra-esophageal manifestations of GERD that include, but are not limited to, acid-related asthma, bronchitis, laryngitis and sleep disorders.
C) other diseases that can be connected to undiagnosed reflux and/or aspiration include, but are not limited to, airway disorders such as asthma, bronchitis, COPD (chronic obstructive pulmonary disease).
D) Helicobacter pylori infection whose eradication is playing a key role in the treatment of gastroin-testinal diseases.
E) Furthermore, "gastrointestinal diseases" comprise other gastrointestinal conditions that might be related to acid secretion, such as Zollinger-Ellison syndrome, acute upper gastrointestinal bleeding, nausea, vomiting due to chemotherapy or post-operative conditions, stress ulceration, IBD (inflam-matory bowel disease) and particularly IBS (irritable bowel syndrome).
In their excellent properties, the active compounds according to the invention surprisingly prove to be clearly superior to the compounds known from the prior art in various models in which the antiul-cerogenic and the antisecretory properties are determined. On account of these properties, the ac-tive compounds according to the invention are outstandingly suitable for use in human and veteri-nary medicine, where they are used, in particular, for the treatment and/or prophylaxis of disorders of the stomach and/or intestine and/or upper digestive tract, particularly of the abovementioned dis-eases.
A further subject of the invention are therefore the active compounds according to the invention for use in the treatment and/or prophylaxis of the abovementioned diseases.
The invention likewise includes the use of the active compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the above-mentioned diseases.
The invention furthermore includes the use of the active compounds according to the invention for the treatment and/or prophylaxis of the abovementioned diseases.
A further subject of the invention are medicaments which comprise one or more active compounds according to the invention.
As medicaments, the active compounds according to the invention are either employed as such, or preferably in combination with suitable pharmaceutical excipients in the form of tablets, coated tab-lets (e.g. film-coated tablets), multi unit particulate system tablets, capsules, suppositories, gran-ules, powders (e.g. lyophilized compounds), pellets, patches (e.g. as TTS
[transdermal therapeutic system]), emulsions, suspensions or solutions. The content of the active compound is advanta-geously being between 0.1 and 95wt% (weight percent in the final dosage form), preferably be-tween 1 and 60wt%. By means of the appropriate selection of the excipients, it is possible to obtain a pharmaceutical administration form adapted to the active compound and/or to the desired onset and/or duration of action (e.g. a sustained release form or a delayed release form).
The active compounds according to the invention can be administered orally, parenterally (e.g. in-travenously), rectally or percutaneously. Oral or intravenous administration is preferred.
The excipients or combinations of excipients which are suitable for the desired pharmaceutical for-mulations are known to the person skilled in the art on the basis of his/her expert knowledge and are composed of one or more accessory ingredients. In addition to solvents, antioxidants, stabiliz-ers, surfactants, complexing agents (e.g. cyclodextrins), the following excipients may be mentioned as examples: For oral administration, gelling agents, antifoams, plasticizer, adsorbent agents, wet-ting agents, colorants, flavorings, sweeteners and/or tabletting excipients (e.g. carriers, fillers, bind-ers, disintegrating agents, lubricants, coating agents); for intravenous administration, dispersants, emulsifiers, preservatives, solubilizers, buffer substances and/or isotonic adjusting substances. For percutaneous administration, the person skilled in the art may choose as excipients, for example:
solvents, gelling agents, polymers, permeation promoters, adhesives, matrix substances and/or wetting agents.
active compounds according to the invention) have valuable pharmacological properties which make them commer-cially utilizable. In particular, they exhibit marked inhibition of gastric acid secretion and an excellent gastric and intestinal protective or curative action in warm-blooded animals, in particular humans. In this connection, the active compounds according to the invention are distinguished by a high selec-tivity of action, a fast onset of action, an advantageous duration of action, efficient control of the du-ration of action by the dosage, a particularly good antisecretory efficacy, the absence of significant side effects and a large therapeutic range.
"Gastric and intestinal protection or cure" in this connection is understood to include, according to general knowledge, the prevention, the treatment and the maintenance treatment of gastrointestinal diseases, in particular of gastrointestinal inflammatory diseases and lesions (such as, for example, reflux esophagitis, gastritis, hyperacidic or drug-related functional dyspepsia, and peptic ulcer dis-ease [including peptic ulcer bleeding, gastric ulcer, duodenal ulcer]), which can be caused, for ex-ample, by microorganisms (e.g. Helicobacter pylori), bacterial toxins, drugs (e.g. certain antiinflam-matories and antirheumatics, such as NSAIDs and COX-inhibitors), chemicals (e.g. ethanol), gas-tric acid or stress situations.
The term "gastrointestinal diseases" is understood to include, according to general knowledge, A) gastroesophageal reflux disease (GERD), the symptoms of which include, but are not limited to, heartburn and/or acid regurgitation and/or non-acid regurgitation.
B) other extra-esophageal manifestations of GERD that include, but are not limited to, acid-related asthma, bronchitis, laryngitis and sleep disorders.
C) other diseases that can be connected to undiagnosed reflux and/or aspiration include, but are not limited to, airway disorders such as asthma, bronchitis, COPD (chronic obstructive pulmonary disease).
D) Helicobacter pylori infection whose eradication is playing a key role in the treatment of gastroin-testinal diseases.
E) Furthermore, "gastrointestinal diseases" comprise other gastrointestinal conditions that might be related to acid secretion, such as Zollinger-Ellison syndrome, acute upper gastrointestinal bleeding, nausea, vomiting due to chemotherapy or post-operative conditions, stress ulceration, IBD (inflam-matory bowel disease) and particularly IBS (irritable bowel syndrome).
In their excellent properties, the active compounds according to the invention surprisingly prove to be clearly superior to the compounds known from the prior art in various models in which the antiul-cerogenic and the antisecretory properties are determined. On account of these properties, the ac-tive compounds according to the invention are outstandingly suitable for use in human and veteri-nary medicine, where they are used, in particular, for the treatment and/or prophylaxis of disorders of the stomach and/or intestine and/or upper digestive tract, particularly of the abovementioned dis-eases.
A further subject of the invention are therefore the active compounds according to the invention for use in the treatment and/or prophylaxis of the abovementioned diseases.
The invention likewise includes the use of the active compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the above-mentioned diseases.
The invention furthermore includes the use of the active compounds according to the invention for the treatment and/or prophylaxis of the abovementioned diseases.
A further subject of the invention are medicaments which comprise one or more active compounds according to the invention.
As medicaments, the active compounds according to the invention are either employed as such, or preferably in combination with suitable pharmaceutical excipients in the form of tablets, coated tab-lets (e.g. film-coated tablets), multi unit particulate system tablets, capsules, suppositories, gran-ules, powders (e.g. lyophilized compounds), pellets, patches (e.g. as TTS
[transdermal therapeutic system]), emulsions, suspensions or solutions. The content of the active compound is advanta-geously being between 0.1 and 95wt% (weight percent in the final dosage form), preferably be-tween 1 and 60wt%. By means of the appropriate selection of the excipients, it is possible to obtain a pharmaceutical administration form adapted to the active compound and/or to the desired onset and/or duration of action (e.g. a sustained release form or a delayed release form).
The active compounds according to the invention can be administered orally, parenterally (e.g. in-travenously), rectally or percutaneously. Oral or intravenous administration is preferred.
The excipients or combinations of excipients which are suitable for the desired pharmaceutical for-mulations are known to the person skilled in the art on the basis of his/her expert knowledge and are composed of one or more accessory ingredients. In addition to solvents, antioxidants, stabiliz-ers, surfactants, complexing agents (e.g. cyclodextrins), the following excipients may be mentioned as examples: For oral administration, gelling agents, antifoams, plasticizer, adsorbent agents, wet-ting agents, colorants, flavorings, sweeteners and/or tabletting excipients (e.g. carriers, fillers, bind-ers, disintegrating agents, lubricants, coating agents); for intravenous administration, dispersants, emulsifiers, preservatives, solubilizers, buffer substances and/or isotonic adjusting substances. For percutaneous administration, the person skilled in the art may choose as excipients, for example:
solvents, gelling agents, polymers, permeation promoters, adhesives, matrix substances and/or wetting agents.
In general, it has been proven advantageous in human medicine to administer the active com-pound(s) in the case of oral administration in a daily dose (given continuously or on-demand) of ap-proximately 0.01 to approximately 20, preferably 0.02 to 5, in particular 0.02 to 1.5, mg/kg of body weight, if appropriate in the form of several, preferably 1 to 2, individual doses to achieve the de-sired result. In the case of a parenteral treatment, similar or (in particular in the case of the intrave-nous administration of the active compounds), as a rule, lower doses can be used. Furthermore, the frequency of administration can be adapted to intermittent, weekly, monthly, even more infre-quent (e.g. implant) dosing. The establishment of the optimal dose and manner of administration of the active compounds necessary in each case can easily be carried out by any person skilled in the art on the basis of his/her expert knowledge.
The medicaments may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmaceutical science. All methods include the step of bringing the active compounds according to the invention into association with the excipients or a combination of excipients. In general the formulations are prepared by uniformly and intimately bringing into association the active compounds according to the invention with liquid excipients or finely divided solid excipients or both and then, if necessary, formulating the product into the de-sired medicament.
The active compounds according to the invention or their pharmaceutical preparations can also be used in combination with one or more pharmacologically active constituents from other groups of drugs [combination partner(s)]. "Combination" is understood to be the supply of both the active compound(s) according to the invention and the combination partner(s) for separate, sequential, simultaneous or chronologically staggered use. A combination is usually designed with the aim of increasing the principal action in an additive or super-additive sense and/or of eliminating or de-creasing the side effects of the combination partner(s), or with the aim to obtain a more rapid onset of action and a fast symptom relief. By choosing the appropriate pharmaceutical formulation of the drugs contained in the combination, the drug release profile of the components can be exactly adapted to the desired effect, e.g. the release of one compound and its onset of action is chrono-logically previous to the release of the other compound.
A combination can be, for example, a composition containing all active compounds (for example a fixed combination) or a kit-of-parts comprising separate preparations of all active compounds.
A "fixed combination" is defined as a combination wherein a first active ingredient and a second ac-tive ingredient are present together in one unit dosage or in a single entity.
One example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture of simultaneous administration, such as in a for-mulation. Another example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in one unit without be-ing in admixture.
A"kit-of -parts" is defined as a combination wherein the said first active ingredient and the said sec-ond active ingredient are present in more than one unit. One example of a"kit-of -parts" is a combi-nation wherein the said first active ingredient and the said second active ingredient are present separately. The components of the kit-of-parts may be administered separately, sequentially, simul-taneously or chronologically staggered.
"Other groups of drugs" are understood to include, for example: tranquillizers (for example from the group of the benzodiazepines, like diazepam), spasmolytics (for example butylscopolaminium bro-mide [Buscopan ]), anticholinergics (for example atropine sulfate, pirenzepine, tolterodine), pain perception reducing or normalizing agents (for example, paracetamol, tetracaine or procaine or es-pecially oxetacain), and, if appropriate, also enzymes, vitamins, trace elements or amino acids.
To be emphasized in this connection is in particular the combination of the active compounds ac-cording to the invention with pharmaceuticals which buffer or neutralize gastric acid (such as, for example, magaldrat, aluminium hydroxide, magnesium carbonate, magnesium hydroxide or other antacids), or especially with pharmaceuticals which inhibit or reduce acid secretion, such as, for ex-ample:
(I) histamine-H2 blockers [e.g. cimetidine, ranitidine], or (II) proton pump inhibitors [e.g. omeprazole, esomeprazole, pantoprazole, lansoprazole, rabepra-zole, tenatoprazole, ilaprazole, leminoprazole, all including their salts and enantiomers] or (III) other potassium-competitive acid blockers [e.g. soraprazan and its stereoisomers, linaprazan, revaprazan, all including their salts]), or (IV) so-called peripheral anticholinergics (e.g. pirenzepine), with gastrin antagonists such as CCK2 antagonists (cholestocystokinin 2 receptor antagonists).
An important combination to be mentioned is the combination with antibacterially active substances, and especially substances with a bactericidal effect, or combinations thereof.
These combination partner(s) are especially useful for the control of Helicobacter pylori infection whose eradication is playing a key role in the treatment of gastrointestinal diseases. As suitable antibacterially active combination partner(s) may be mentioned, for example:
(A) cephalosporins, such as, for example, cifuroximaxetil (B) penicillines, such as, for example, amoxicillin, ampicillin (C) tetracyclines, such as, for example, tetracyline itself, doxycycline (D) (3-lactamase inhibitors, such as, for example, clavulanic acid (E) macrolide antibiotics, such as, for example, erythromycin, clarithromycin, azithromycin (F) rifamycines, such as, for example, rifamycine itself (G) glycoside antibiotics, such as, for example, gentamicin, streptomycin (H) gyrase inhibitors, such as, for example, ciprofloxaxin, gatifloxacin, moxifloxacin (I) oxazolidines, such as, for example, linezolid (J) nitrofuranes or nitroimidazoles, such as, for example, metronidazole, tinidazole, nitrofurantoin (K) bismuth salts, such as, for example, bismuth subcitrat (L) other antibacterially active substances and combinations of substances selected from (A) to (L), for example clarithromycin + metronida-zole. Preferred is the use of two combination partners. Preferred is the use of two combination part-ners selected from amoxicillin, clarithromycin and metronidazole. A preferred example is the use of amoxicillin and clarithromycin.
In view of their excellent activity regarding gastric and intestinal protection or cure, the active com-pounds according to the invention are especially suited for a free or fixed combination with drugs, which are known to cause "drug-induced dyspepsia" or are known to have a certain ulcerogenic po-tency, such as, for example, acetylsalicylic acid, certain antiinflammatories and antirheumatics, such as NSAIDs (non-steroidal antiinflammatory drugs, e.g. etofenamate, diclofenac, indometacin, ibuprofen, piroxicam, naproxen, meloxicam), oral steroids, bisphosponates (e.g. alendronate), or even NO-releasing NSAIDs, COX-2 inhibitors (e.g. celecoxib, lumiracoxib).
In addition, the active compounds according to the invention are suited for a free or fixed combina-tion with motility-modifying or -regulating drugs (e.g. gastroprokinetics like mosapride, tegaserod, itopride, metoclopramid), and especially with pharmaceuticals which reduce or normalize the inci-dence of transient lower esophageal sphincter relaxation (TLESR), such as, for example, GABA-B
agonists (e.g. baclofen, (2R)-3-amino-2-fluoropropylphosphinic acid) or allosteric GABA-B agonists (e.g. 3,5-bis(1,1-dimethylethyl)-4-hydroxy-(3,(3-dimethylbenzenepropanol), GABA-B re-uptake inhibi-tors (e.g. tiagabine), metabotropic glutamate receptor type 5(mGIuR5) antagonists (e.g. 2-methyl-6-(phenylethynyl)pyridine hydrochloride), CB2 (cannabinoid receptor) agonists (e.g. [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3,de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone mesylate). Pharmaceuticals used for the treatment of IBS or IBD are also suitable com-bination partner(s), such as, for example: 5-HT4 receptor agonists like mosapride, tegaserod; 5-HT3 receptor antagonists like alosetron, cilansetron; NK2 antagonists like saredutant, nepadutant;
ic-opiate agonists like fedotozine.
Suitable combination partner(s) also comprise airway therapeutica, for example for the treatment of acid-related asthma and bronchitis. In some cases, the use of a hypnotic aid (such as, for example, Zolpidem [Bikalm ]) as combination partner(s) may be rational, for example for the treatment of GERD-induced sleep disorders.
The medicaments may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmaceutical science. All methods include the step of bringing the active compounds according to the invention into association with the excipients or a combination of excipients. In general the formulations are prepared by uniformly and intimately bringing into association the active compounds according to the invention with liquid excipients or finely divided solid excipients or both and then, if necessary, formulating the product into the de-sired medicament.
The active compounds according to the invention or their pharmaceutical preparations can also be used in combination with one or more pharmacologically active constituents from other groups of drugs [combination partner(s)]. "Combination" is understood to be the supply of both the active compound(s) according to the invention and the combination partner(s) for separate, sequential, simultaneous or chronologically staggered use. A combination is usually designed with the aim of increasing the principal action in an additive or super-additive sense and/or of eliminating or de-creasing the side effects of the combination partner(s), or with the aim to obtain a more rapid onset of action and a fast symptom relief. By choosing the appropriate pharmaceutical formulation of the drugs contained in the combination, the drug release profile of the components can be exactly adapted to the desired effect, e.g. the release of one compound and its onset of action is chrono-logically previous to the release of the other compound.
A combination can be, for example, a composition containing all active compounds (for example a fixed combination) or a kit-of-parts comprising separate preparations of all active compounds.
A "fixed combination" is defined as a combination wherein a first active ingredient and a second ac-tive ingredient are present together in one unit dosage or in a single entity.
One example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture of simultaneous administration, such as in a for-mulation. Another example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in one unit without be-ing in admixture.
A"kit-of -parts" is defined as a combination wherein the said first active ingredient and the said sec-ond active ingredient are present in more than one unit. One example of a"kit-of -parts" is a combi-nation wherein the said first active ingredient and the said second active ingredient are present separately. The components of the kit-of-parts may be administered separately, sequentially, simul-taneously or chronologically staggered.
"Other groups of drugs" are understood to include, for example: tranquillizers (for example from the group of the benzodiazepines, like diazepam), spasmolytics (for example butylscopolaminium bro-mide [Buscopan ]), anticholinergics (for example atropine sulfate, pirenzepine, tolterodine), pain perception reducing or normalizing agents (for example, paracetamol, tetracaine or procaine or es-pecially oxetacain), and, if appropriate, also enzymes, vitamins, trace elements or amino acids.
To be emphasized in this connection is in particular the combination of the active compounds ac-cording to the invention with pharmaceuticals which buffer or neutralize gastric acid (such as, for example, magaldrat, aluminium hydroxide, magnesium carbonate, magnesium hydroxide or other antacids), or especially with pharmaceuticals which inhibit or reduce acid secretion, such as, for ex-ample:
(I) histamine-H2 blockers [e.g. cimetidine, ranitidine], or (II) proton pump inhibitors [e.g. omeprazole, esomeprazole, pantoprazole, lansoprazole, rabepra-zole, tenatoprazole, ilaprazole, leminoprazole, all including their salts and enantiomers] or (III) other potassium-competitive acid blockers [e.g. soraprazan and its stereoisomers, linaprazan, revaprazan, all including their salts]), or (IV) so-called peripheral anticholinergics (e.g. pirenzepine), with gastrin antagonists such as CCK2 antagonists (cholestocystokinin 2 receptor antagonists).
An important combination to be mentioned is the combination with antibacterially active substances, and especially substances with a bactericidal effect, or combinations thereof.
These combination partner(s) are especially useful for the control of Helicobacter pylori infection whose eradication is playing a key role in the treatment of gastrointestinal diseases. As suitable antibacterially active combination partner(s) may be mentioned, for example:
(A) cephalosporins, such as, for example, cifuroximaxetil (B) penicillines, such as, for example, amoxicillin, ampicillin (C) tetracyclines, such as, for example, tetracyline itself, doxycycline (D) (3-lactamase inhibitors, such as, for example, clavulanic acid (E) macrolide antibiotics, such as, for example, erythromycin, clarithromycin, azithromycin (F) rifamycines, such as, for example, rifamycine itself (G) glycoside antibiotics, such as, for example, gentamicin, streptomycin (H) gyrase inhibitors, such as, for example, ciprofloxaxin, gatifloxacin, moxifloxacin (I) oxazolidines, such as, for example, linezolid (J) nitrofuranes or nitroimidazoles, such as, for example, metronidazole, tinidazole, nitrofurantoin (K) bismuth salts, such as, for example, bismuth subcitrat (L) other antibacterially active substances and combinations of substances selected from (A) to (L), for example clarithromycin + metronida-zole. Preferred is the use of two combination partners. Preferred is the use of two combination part-ners selected from amoxicillin, clarithromycin and metronidazole. A preferred example is the use of amoxicillin and clarithromycin.
In view of their excellent activity regarding gastric and intestinal protection or cure, the active com-pounds according to the invention are especially suited for a free or fixed combination with drugs, which are known to cause "drug-induced dyspepsia" or are known to have a certain ulcerogenic po-tency, such as, for example, acetylsalicylic acid, certain antiinflammatories and antirheumatics, such as NSAIDs (non-steroidal antiinflammatory drugs, e.g. etofenamate, diclofenac, indometacin, ibuprofen, piroxicam, naproxen, meloxicam), oral steroids, bisphosponates (e.g. alendronate), or even NO-releasing NSAIDs, COX-2 inhibitors (e.g. celecoxib, lumiracoxib).
In addition, the active compounds according to the invention are suited for a free or fixed combina-tion with motility-modifying or -regulating drugs (e.g. gastroprokinetics like mosapride, tegaserod, itopride, metoclopramid), and especially with pharmaceuticals which reduce or normalize the inci-dence of transient lower esophageal sphincter relaxation (TLESR), such as, for example, GABA-B
agonists (e.g. baclofen, (2R)-3-amino-2-fluoropropylphosphinic acid) or allosteric GABA-B agonists (e.g. 3,5-bis(1,1-dimethylethyl)-4-hydroxy-(3,(3-dimethylbenzenepropanol), GABA-B re-uptake inhibi-tors (e.g. tiagabine), metabotropic glutamate receptor type 5(mGIuR5) antagonists (e.g. 2-methyl-6-(phenylethynyl)pyridine hydrochloride), CB2 (cannabinoid receptor) agonists (e.g. [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3,de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone mesylate). Pharmaceuticals used for the treatment of IBS or IBD are also suitable com-bination partner(s), such as, for example: 5-HT4 receptor agonists like mosapride, tegaserod; 5-HT3 receptor antagonists like alosetron, cilansetron; NK2 antagonists like saredutant, nepadutant;
ic-opiate agonists like fedotozine.
Suitable combination partner(s) also comprise airway therapeutica, for example for the treatment of acid-related asthma and bronchitis. In some cases, the use of a hypnotic aid (such as, for example, Zolpidem [Bikalm ]) as combination partner(s) may be rational, for example for the treatment of GERD-induced sleep disorders.
Claims (11)
1. A compound of the formula 1 in which R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy- 1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hydroxy-1-4C-alkyl, R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxycarbon-yl, hydroxy-1-4C-alkyl, halogen, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, flu-oro-1-4C-alkyl, mono- or di-1-4C-alkylamino-1-4C-alkyl or cyanomethyl, R3 is hydrogen, halogen, fluoro-1-4C-alkyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alk-oxy-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl or 1-4C-alkoxycarbonyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl, or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluoraze-tidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, hydroxy-1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy, 2-4C-alkenyloxy, 1-4C-alkylcarbonyl, carboxyl, 1-4C-alkoxycarbonyl, carboxy-1-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, halogen, hydroxyl, trifluoromethyl, halo-1-4C-alkoxy, nitro, amino, mono- or di-1-4C-alkylamino, 1-4C-alkyl-carbonylamino, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or sulfonyl, and its salts.
2. A compound of the formula 1 as claimed in claim 1, R1 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl, R2 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or halogen, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or the group -CO-NR31R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluorazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are identical or different substituents selected from the group consisting of hydro-gen, 1-4C-alkyl or halogen, and its salts.
3. A compound of the formula 1 as claimed in claim 1, in which R1 is 1-4C-alkyl, R2 is hydrogen or 1-4C-alkyl, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl or the group -CO-NR31R32, where R31 is hydrogen, hydroxyl, 1-7C-alkyl, 3-7C-cycloalkyl, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl or 1-4C-alkylcarbonyl-1-4C-alkyl and R32 is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where R31 and R32 together, including the nitrogen atom to which both are bonded, are a pyr-rolidino, hydroxypyrrolidino, piperidino, piperazino, azetidino, hydroxyazetidino, fluorazetidino, aziridino, N-1-4C-alkylpiperazino or morpholino group, R4 and R5 are each hydrogen, and its salts.
4. A compound of the formula 1 as claimed in claim 1, in which R1 is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl or the group -CO-NR31R32 where R31 is 1-7C-alkyl and R32 is hydrogen, R4 and R5 are each hydrogen, and its salts.
5. A compound of the formula 1 as claimed in claim 1, in which R1 is 1-4C-alkyl, R2 is 1-4C-alkyl, R3 is hydrogen R4 and R5 are each hydrogen, and its salts.
6. A compound of the formula 1 as claimed in claim 1, in which the substituents R1, R2, R3, R4 and R5 have the meanings given in the following table, whereby Me is CH3 and Et is C2H5 Me Me CH2OH H H
Me Me CH2OCH3 H H
Me Me C(O)NHMe H H
Me Me C(O)N-pyrrolidine H H
Me Me C(O)NH(CH2)2OH H H
Me Me C(O)NH(CH2)2OMe H H
Me Me C(O)NH2 H H
Me Me C(O)N-morpholine H H
Me Me C(O)NMe2 H H
Me Me C(O)N-aziridine H H
Me Me C(O)OEt H H
Me Me C(O)OH H H
Me Me C(O)N-azetidine H H
Me Me C(O)NH(CH2)2Me H H
Me Me C(O)NHCH2CH(OH)CH2OH H H
Me Me C(O)NH-cyclopropyl H H
Me Me H H H
Me Me C(O)NHEt H H
Me Me C(O)NH(CH2)3OH H H
Me Me C(O)NH(CH2)3OMe H H
Me Me C(O)NHCH2C(O)CH3 H H
Me Me C(O)N-3-fluorazetidine H H
Me Me C(O)N(CH3)-(CH2)2OH H H
Me Me C(O)N(CH3)-(CH2)2OMe H H
Me Me C(O)N(CH3)-(CH2)3OH H H
Me Me C(O)N(CH3)-(CH2)3OMe H H
Me H CH2OH H H
Me H CH2OCH3 H H
Me H C(O)NHMe H H
Me H C(O)N-pyrrolidine H H
Me H C(O)NH(CH2)2OH H H
Me H C(O)NH(CH2)2OMe H H
Me H C(O)NH2 H H
Me H C(O)N-morpholine H H
Me H C(O)NMe2 H H
Me H C(O)N-aziridine H H
Me H C(O)OEt H H
Me H C(O)OH H H
Me H C(O)N-azetidine H H
Me H C(O)NH(CH2)2Me H H
Me H C(O)NHCH2CH(OH)CH2OH H H
Me H C(O)NH-cyclopropyl H H
Me H H H H
Me H C(O)NHEt H H
Me H C(O)NH(CH2)3OH H H
Me H C(O)NH(CH2)3OMe H H
Me H C(O)NHCH2C(O)CH3 H H
Me H C(O)N-3-fluorazetidine H H
Me H C(O)N(CH3)-(CH2)2OH H H
Me H C(O)N(CH3)-(CH2)2OMe H H
Me H C(O)N(CH3)-(CH2)3OH H H
Me H C(O)N(CH3)-(CH2)3OMe H H
and its salts.
Me Me CH2OCH3 H H
Me Me C(O)NHMe H H
Me Me C(O)N-pyrrolidine H H
Me Me C(O)NH(CH2)2OH H H
Me Me C(O)NH(CH2)2OMe H H
Me Me C(O)NH2 H H
Me Me C(O)N-morpholine H H
Me Me C(O)NMe2 H H
Me Me C(O)N-aziridine H H
Me Me C(O)OEt H H
Me Me C(O)OH H H
Me Me C(O)N-azetidine H H
Me Me C(O)NH(CH2)2Me H H
Me Me C(O)NHCH2CH(OH)CH2OH H H
Me Me C(O)NH-cyclopropyl H H
Me Me H H H
Me Me C(O)NHEt H H
Me Me C(O)NH(CH2)3OH H H
Me Me C(O)NH(CH2)3OMe H H
Me Me C(O)NHCH2C(O)CH3 H H
Me Me C(O)N-3-fluorazetidine H H
Me Me C(O)N(CH3)-(CH2)2OH H H
Me Me C(O)N(CH3)-(CH2)2OMe H H
Me Me C(O)N(CH3)-(CH2)3OH H H
Me Me C(O)N(CH3)-(CH2)3OMe H H
Me H CH2OH H H
Me H CH2OCH3 H H
Me H C(O)NHMe H H
Me H C(O)N-pyrrolidine H H
Me H C(O)NH(CH2)2OH H H
Me H C(O)NH(CH2)2OMe H H
Me H C(O)NH2 H H
Me H C(O)N-morpholine H H
Me H C(O)NMe2 H H
Me H C(O)N-aziridine H H
Me H C(O)OEt H H
Me H C(O)OH H H
Me H C(O)N-azetidine H H
Me H C(O)NH(CH2)2Me H H
Me H C(O)NHCH2CH(OH)CH2OH H H
Me H C(O)NH-cyclopropyl H H
Me H H H H
Me H C(O)NHEt H H
Me H C(O)NH(CH2)3OH H H
Me H C(O)NH(CH2)3OMe H H
Me H C(O)NHCH2C(O)CH3 H H
Me H C(O)N-3-fluorazetidine H H
Me H C(O)N(CH3)-(CH2)2OH H H
Me H C(O)N(CH3)-(CH2)2OMe H H
Me H C(O)N(CH3)-(CH2)3OH H H
Me H C(O)N(CH3)-(CH2)3OMe H H
and its salts.
7. A compound of the formula 5, in which R1, R2, R3, R4 and R5 are defined as in claim 1 for compounds of the formula 1.
8. A compound of the formula 2, in which R1, R2, R3, R4 and R5 are defined as in claim 1 for compounds of the formula 1.
9. Use of a compound according to any of claims 1 to 6 for the production of medicaments which are employed for the treatment and/or prophylaxis of gastrointestinal disorders.
10. A medicament comprising one or more compounds according to any of claims 1 to 6 and/or a pharmaceutically acceptable salt thereof together with customary pharmaceutical auxiliaries and/or excipients.
11. The use of a compound according to any of claims 1 to 6 and its pharmaceutically acceptable salts for the prevention and/or treatment of gastrointestinal disorders.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05105327.0 | 2005-06-16 | ||
EP05105327 | 2005-06-16 | ||
PCT/EP2006/063164 WO2006134112A1 (en) | 2005-06-16 | 2006-06-13 | Spiro-imidaznaphthyridine derivatives as gastric acid secretion inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2610920A1 true CA2610920A1 (en) | 2006-12-21 |
Family
ID=34940190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002610920A Abandoned CA2610920A1 (en) | 2005-06-16 | 2006-06-13 | Spiro-imidaznaphthyridine derivatives as gastric acid secretion inhibitors |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1899341A1 (en) |
JP (1) | JP2008543809A (en) |
AR (1) | AR054772A1 (en) |
AU (1) | AU2006259124A1 (en) |
CA (1) | CA2610920A1 (en) |
TW (1) | TW200716637A (en) |
WO (1) | WO2006134112A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0001555A3 (en) * | 1997-10-30 | 2001-01-29 | Altana Pharma Ag | Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation |
JP2005504761A (en) * | 2001-08-10 | 2005-02-17 | アルタナ ファルマ アクチエンゲゼルシャフト | Tricyclic imidazopyridine |
-
2006
- 2006-06-09 AR ARP060102419A patent/AR054772A1/en not_active Application Discontinuation
- 2006-06-13 CA CA002610920A patent/CA2610920A1/en not_active Abandoned
- 2006-06-13 WO PCT/EP2006/063164 patent/WO2006134112A1/en active Application Filing
- 2006-06-13 AU AU2006259124A patent/AU2006259124A1/en not_active Abandoned
- 2006-06-13 JP JP2008516304A patent/JP2008543809A/en active Pending
- 2006-06-13 EP EP06763685A patent/EP1899341A1/en not_active Withdrawn
- 2006-06-15 TW TW095121461A patent/TW200716637A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006259124A8 (en) | 2008-04-03 |
AR054772A1 (en) | 2007-07-18 |
AU2006259124A1 (en) | 2006-12-21 |
JP2008543809A (en) | 2008-12-04 |
WO2006134112A1 (en) | 2006-12-21 |
EP1899341A1 (en) | 2008-03-19 |
TW200716637A (en) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070191334A1 (en) | Tricyclic imidazopyridines | |
US20090093473A1 (en) | Spiro-benzimidazoles as inhibitors of gastric acid secretion | |
US20080113962A1 (en) | Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders | |
US20060194968A1 (en) | Cyclic benizimidazoles | |
US7326718B2 (en) | 8-Substituted imidazopyridines | |
EP1934215A1 (en) | Isotopically substituted imidazopyridine derivatives for the treatment of gastrointestinal disorders | |
WO2008015196A1 (en) | 5-,7-bis-substituted imidazo[1,2-a]pyridines | |
WO2008151927A2 (en) | 6-n-substituted benz imidazole derivatives as acid pump antagonists | |
EP1758900B1 (en) | Substituted tricyclic benzimidazoles | |
CA2610920A1 (en) | Spiro-imidaznaphthyridine derivatives as gastric acid secretion inhibitors | |
WO2008084067A2 (en) | Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives | |
US20070244173A1 (en) | 6,7-Dihydroxy-8-Phenyl-3,6,7,8-Tetrahydro-Chromeno [7,8-d] Imidazole Derivatives and Their Use as Gastric Acid Secretion Inhibitors | |
WO2008071766A2 (en) | Spiro-indene substituted imidazonaphythyridine and pyranoimidazopyridine derivatives as inhibitors of gastric acid secretion | |
US20080114020A1 (en) | Difluoro-Substituted Imidazopyridines | |
EP1697357A2 (en) | Tricyclic benzimidazoles | |
WO2008017466A1 (en) | Pharmaceutically active tetrahydroisoquinoline-substituted benzimidazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |